Adeno-Associated Virus (AAV) Gene Delivery: Dissecting Molecular Interactions upon Cell Entry

Edward E. Large, Mark A. Silveria, Grant M. Zane, Onellah Weerakoon and Michael S. Chapman *

Department of Biochemistry, University of Missouri, Columbia, MO 65201, USA; largeee@missouri.edu (E.E.L.); msilveria@mail.missouri.edu (M.A.S.); zaneg@missouri.edu (G.M.Z.); opw4m7@mail.missouri.edu (O.W.)

* Correspondence: chapmanms@missouri.edu; Tel.: +1-573-882-9825

Abstract: Human gene therapy has advanced from twentieth-century conception to twenty-first-century reality. The recombinant Adeno-Associated Virus (rAAV) is a major gene therapy vector. Research continues to improve rAAV safety and efficacy using a variety of AAV capsid modification strategies. Significant factors influencing rAAV transduction efficiency include neutralizing antibodies, attachment factor interactions and receptor binding. Advances in understanding the molecular interactions during rAAV cell entry combined with improved capsid modulation strategies will help guide the design and engineering of safer and more efficient rAAV gene therapy vectors.

Keywords: adeno-associated virus; AAV; gene therapy; virus structure; AAV receptor; AAV attachment factor

1. Introduction

1.1. AAV Biotechnology

AAV is the basis of a multi-billion dollar industry and hundreds of clinical trials used AAV delivery systems [1]. Viral vector biotechnology is a leading choice for gene therapy platforms and recombinant Adeno-Associated Virus (rAAV) vectors are typically preferred due to low toxicity [2], dependence upon other viruses for replication [3], broad tropism and the ability to infect both dividing and non-dividing cells. There are currently two AAV gene replacement treatments available for autosomal recessive genetic disorders: Luxturna and Zolgensma. Luxturna rAAV is based on the AAV2 serotype (rAAV2) and delivers a functional copy of the RPE65 (retinal pigment epithelium-specific 65 kDa protein) gene to the retinal pigment epithelial cells of patients with retinal dystrophy [4]. Zolgensma uses rAAV9 to deliver a functional copy of the human SMN1 (survival of motor neuron 1) gene to spinal muscular atrophy (SMA) patients [5]. SMA is the most common fatal single gene disease in infants, and it is caused by an autosomal recessive mutation in the survival motor neuron 1 gene (SMN1). More rAAV therapies are in the pipeline, and dozens of clinical trials are currently underway [6]. Thus, the range of rAAV treatment options and efficacy of AAV as a therapeutic vector continues to grow.

rAAV is a successful gene therapy biopharmaceutical, but more efficient rAAV vectors that can be delivered at lower doses are still needed. For example, high rAAV doses were implicated in the recent tragic deaths of three AAV gene therapy patients during X-linked myotubular myopathy Phase I/II clinical trials [7]. The trial administered an AAV8 serotype containing a wild-type copy of the MTM1 gene at various doses. Immune toxicity was observed in those with liver disease, obesity or at older age at the highest dose (3 × 10¹⁴ vg/kg; vector genomes/kilogram) [7]. The immunotoxicity of rAAV is less severe than adenoviral or lentiviral vectors [8,9], but these patient deaths are a grim reminder of the need for improved AAV vectors that can be delivered at lower doses. rAAV vectors that avoid antibody neutralization or vectors with improved transduction efficiency would significantly reduce the rAAV gene therapy doses needed to cure previously incurable diseases.
rAAV production continues to be updated and evaluated for industrial-scale production of next-generation rAAV therapies. Commercial and research rAAV production typically involves a “triple transfection” approach. Triple transfection components consist of a plasmid encoding the transgene, a helper plasmid containing Adenovirus type-5 (Ad5) helper genes (i.e., E1a/b, E2a, E4 and VA RNA) or their equivalents and another plasmid encoding the rAAV Rep and Cap proteins [10–13]. Variations include combined helper and rAAV plasmid functions on a single plasmid or stable expression of helper functions, pre-programmed into mammalian cell lines [14]. Vector production improvement focuses on particle metrics such as the ratio of empty to non-empty vector particles. Increasing the number of full particles decreases the number of particles needed for gene therapy and subsequently improves safety and efficacy [15].

rAAV gene therapy technology is derived from a small (~25 nm diameter) non-enveloped wild-type AAV (wtAAV) ssDNA virus in the family Parvoviridae. wtAAV serotypes from diverse primate lineages must navigate common human biological barriers. Human wtAAV serotypes have been studied extensively, and the most well-understood primate family members are serotypes AAV1-9. Serological and sequence classifications indicate unique origins for the most divergent serotypes, AAV4 and AAV5. Other serotypes can be grouped by clade, with representative serotypes listed parenthetically: A (AAV1/6), B (AAV2), C (AAV3/13), D (AAV7), E (AAV8/10) and F (AAV9) (Table 1) [16]. Four additional serotypes (AAV10-13) [17–19] were isolated after the classification of AAV1-9. Structural similarities of AAV11 and AAV12 to AAV4 place the three in a potential clade whereas structural similarities of AAV13 to AAV3 suggest AAV13 is in clade C [20]. These primate serotypes serve as the primary basis for rAAV biotechnology.

Table 1. Native AAV structures.

| Serotype   | Clade | Resolution | Year | Tropism 1 | Tropism 2 | Tropism 3 | Kpobid        | Reference                  |
|------------|-------|------------|------|-----------|-----------|-----------|----------------|-----------------|
| AAV1       | A     | X-ray 2.5 Å| 2010 | Muscle, CNS, heart | Skin, lung, kidney, cervix, bone | Kidney, skin | 3NG9          | Ng et al. [21]   |
| AAV2       | B     | X-ray 3.0 Å| 2002 | Liver, CNS, muscle | Skin, lung, kidney, cervix, liver, bone | Liver, kidney, cervix, retina, skin | 1LP3          | Xie et al. [22]  |
| AAV3       | C     | X-ray 2.6 Å| 2010 | Muscle, stem cells | Skin, lung, kidney, cervix, liver, bone | Skin | 3KIC          | Lerch et al. [23] |
| AAV4       | Unique | X-ray 3.2 Å| 2006 | Eye, CNS | Bone | Not detected | 2G8G          | Govindasamy et al. [24] |
| AAV5       | Unique | X-ray 3.5 Å| 2013 | CNS, lung, eye | Not detected | Not detected | 3NTT          | Govindasamy et al. [25] |
| AAV6       | A     | X-ray 3.0 Å| 2011 | Muscle, CNS, heart, lung | Skin, lung, kidney, cervix, bone | Skin | 4V86          | Xie et al. [26]  |
| AAV7       | D     | Cryo-EM 3.0 Å| 2021 | Muscle, CNS | Liver, muscle, pancreas, CNS | Not detected | 7L5Q          | Mietzsch et al. [20] |
| AAV8       | E     | X-ray 2.6 Å| 2007 | Not detected | Not detected | Not detected | 2QA0          | Nam et al. [27]  |
| AAV9       | F     | X-ray 2.8 Å| 2012 | Not detected | Not detected | Not detected | 3UX1          | Dimattia et al. [28] |
| AAVrh.39   | Unique |            |      | Muscle (AAV10) | Not tested | Not tested | 6V1T          | Mietzsch et al. [29] |
| AAV11      | Cryo-EM 2.9 Å| 2021 | Unknown | Not tested | Not tested | Not tested | 7L6F          | Mietzsch et al. [20] |
| AAV12      | Cryo-EM 2.5 Å| 2021 | Nasal | Not tested | Not tested | Not tested | 7L6B          | Mietzsch et al. [20] |
| AAV13      | Cryo-EM 3.0 Å| 2021 | Not shown | Not tested | Not tested | Not tested | 7L6L          | Mietzsch et al. [20] |
| AAVDJ      | Cryo-EM 4.5 Å| 2012 | Not shown | Not tested | Not tested | Not tested | 3JIQ          | Lerch et al. [30] |
| AAVDJ      | Cryo-EM 1.6 Å| 2020 | Not shown | Not tested | Not tested | Not tested | 7KFR          | Xie et al. [31]  |

1 Li and Samulski 2020 [32], Review; 2 Ellis et al. 2013 [33], Supplementary Table S2; 3 Grimm et al. 2008 [34], Supplementary Table S2.

rAAV capsids face several significant hurdles before uncoating in the nucleus, and this is an essential area of research for improving vector designs. First, the capsids must avoid pre-existing antibodies and interact with cellular attachment factors and cell entry receptors. After cell entry, rAAV vectors are trafficked to the nucleus where rAAV particles
are uncoated. This review focuses on rAAV vector engineering strategies and known cell entry interactions affecting rAAV transduction. It will focus on the capsid, recognizing that, in terms of immune response, the transgene can have varied specific effects, and that vector DNA or derived RNA could also trigger immune responses, topics that are garnering increasing attention and have been reviewed recently elsewhere [35].

1.2. AAV Molecular Biology

AAV2 is the canonical AAV serotype (or “type species”) for the AAV family and provides a valuable reference for studying other AAVs. For example, AAV2 was used to characterize the first AAV glycan attachment factors and deduce the first high-resolution AAV structure, and AAV2 served as the basis for the first genome-wide screen to identify protein entry receptors [22,24,36,37]. More recently, AAV2 was the model serotype for systematic genotype-phenotype investigation [38].

The AAV2 genome contains ~4.7 kb of ssDNA flanked by inverted terminal repeats (ITRs) and encodes two primary gene sets; rep and cap (Figure 1a). The 5’ region of the genome encodes four Rep proteins from a single open reading frame (ORF) (Rep40, Rep52, Rep68, and Rep78). The Rep proteins are involved in virus replication, packaging and integration. Rep78/68 possess helicase/endonuclease activity and bind to the ITRs [39], while Rep52/40 possess 3’-to-5’ helicase activity and are responsible for the packaging of viral genomes into the capsid [40]. The 3’ genome region encodes the three AAV capsid proteins VP1, VP2, and VP3 in the same ORF with respective sizes of 87 kDa, 72 kDa, and 62 kDa. The AAV2 VP3 region (533 amino acids (aa)) is common to VP1-3, and structures of the N-terminal regions unique to VP2 (65 aa) and VP1 (202 aa) remain unsolved (Figure 1b). The unique region of VP1 (abbreviated VP1u) contains a phospholipase domain important in AAV trafficking from endosomes to the nucleus [41]. The VP1-3 genomic region encodes the proteins that form the viral capsid and, in turn, determines both antibody recognition epitopes and receptor binding sites.

In addition to VP1-3, the ~2.2 kb cap region encodes at least three known alternate reading frames (i.e., overprinted regions; Figure 1a). The 5’ region of the AAV2 cap coding region contains the recently discovered 119 amino acid MAAP protein [38] and the AAP protein (204 aa) [42–47]. The X gene encodes a protein of 172 amino acids at the 3’ end of the VP1 coding region [38,48–50]. The functions of these overprinted regions continue to be an active area of research.

The VP1u domain is important for rAAV transduction. The first three of four basic regions (BR1-4) are involved in nuclear localization [51] and BR1 is specific to VP1u while BR2-3 are part of VP1/2. The AAV VP1u domain also encodes a calcium-dependent group XIII phospholipase A2 (PLA2) enzyme [52] and a calcium-binding domain. The enzymatic activity of PLA2 is vital for AAV endosome escape [41,53]. Multiple structures exist for other PLA2 enzymes in unbound or inhibitor-complex states, but no structures exist for parvovirus versions.

The structural properties of the AAV capsid are crucial determinants in rAAV production, purification, and cargo delivery. Cap proteins must form a stable 60-mer capsid containing the desired transgene cargo. The amino acid sequence of the cap region of rAAV plasmids also encodes capsid regions responsible for tissue tropism, antigenicity and interactions with cell entry factors [54]. Given the role of the capsid in delivering therapeutic transgenes into the cell and trafficking to the nucleus, capsid structure will be a key focus of this review, both as a foundation for understanding and modulating the underlying molecular interactions and as a foundation for understanding the limits on modifying the virus in immune evasion.

1.3. The First High-Resolution Dependovirus Structure

Among the first atomic structures for icosahedral capsids were plant viruses with a conserved β-barrel motif [55]. The motif consists of eight antiparallel β strands [56] and is also known as a jelly-roll [57]. The β-barrel is not fully continuous but is more aptly
described as a sandwich of two sheets, each comprised of at least four antiparallel strands (lettered BIDG and CHEF). As in many other viruses, the jelly-roll β barrel is the foundation for parvovirus capsid proteins, but some of the loops between strands are several times longer than in those previously seen [58].

![Diagram of AAV2 genome and VP1/2 region](image-url)

**Figure 1.** The AAV2 genome and VP1/2 region. (a) Rep/Cap plasmids (top of panel) encode multiple proteins (light blue = Rep; green = Cap). The linear ssDNA wtAAV2 genome is flanked by inverted terminal repeats (ITRs). Four Rep proteins are produced in the 5’ coding region (left side = light blue). VP1-3, AAP, MAAP, and X proteins are expressed in the 3’ region (right side = green). The dashed line rectangle surrounds the VP3 common region of VP1-3, which produces known native AAV structures (Table 1). (b) The VP1/2 region contains basic regions 1-3 (BR1-3), a phospholipase A2 (PLA2) enzyme and a calcium binding domain (CBD).

Parvovirus capsids comprise sixty monomers in icosahedral symmetry (T = 1). The family contains three subfamilies: *Parvovirinae*, *Densovirinae*, and *Hamaparvovirinae* [59]. *Parvovirinae* infect the dividing cells of vertebrates and *Densovirinae* infect dividing arthropod cells while the newly classified *Hamaparvovirinae* (Greek *hama* = together) subfamily contains members that infect vertebrate and invertebrate hosts [59]. Four high-resolution *Parvoviridae* family structures provided early insights into autonomous vertebrate *Parvovirinae* structures: canine parvovirus (CPV; Tsao et al., 1991 [58]), feline panleukopenia virus (FPV; Agbandje et al., 1993 [60]), minute virus of mouse (MVM; Agbandje-McKenna et al., 1998 [61]), and porcine parvovirus (PPV; Simpson et al., 2002 [62]). Key features of parvovirus structures include a 3-fold proximal spike which varies in prominence, a large shallow canyon surrounding the 5-fold axis, and a small depression/valley centered on the 2-fold axis between two 3-fold spikes (Figure 2a). An invertebrate parvovirus structure from the *Densovirinae* subfamily, the wax moth (*Galleria mellonella*) densovirus (*GmDNV*), indicated significant differences from the vertebrate parvovirus structures [63]. The β barrel topology is conserved but the long GH loop of vertebrate parvoviruses is mostly missing [57,64]. The absence of a long GH loop in *GmDNV* leads to a much flatter surface topology than for the other parvoviruses that face adaptive immune systems.

The 3 Å X-ray crystallography structure of AAV2 [22] was the first high-resolution *Dependovirus* structure and provided structurally-guided insights into virus capsid evolution (Figure 2a). AAV and autonomous parvovirus VP1 amino acids sequences are not similar.
(<24% amino acid identity) [65]. Nevertheless, there is high structural homology with the mammalian autonomous parvoviruses, sharing the β barrel and the presence of a long GH loop, if not details of its structure [22,57]. AAV serotype structures have variable regions (VR) with higher sequence diversity [24]. The majority of VR are found in the GH loop within regions responsible for antibody evasion and cell entry (Figure 2b,c). Therefore, the AAV2 structure provided a much-needed reference for understanding Dependovirus diversity and a three-dimensional map for understanding the molecular mechanisms of cellular entry.

Figure 2. The AAV2 structure. (a) AAV2 60-mer colored by radial distance from the center of the virion; 2-fold, 3-fold, and 5-fold axes are indicated by arrows and associated variable regions (VR) are noted. A small icosahedron is provided in the lower right corner showing 2-fold (black oval), 3-fold (red triangle), and 5-fold (blue pentagon) axes along with kite-shaped quadrilaterals to denote schematically the approximate juxtaposition of subunits. (b) AAV2 jelly-roll β barrel strands form the inner surface of the capsid subunit and are highlighted in blue. AAV loops constituting more than half of the structure, colored yellow, are on the outer surface of the capsid. Sequence-variable regions are highlighted in red. (c) The topology of the β barrel is shown schematically in the center, with blue arrows of length proportional to the number of strand residues. Loops vary in size and complexity. Structures in panels (a,b) were prepared using PyMOL [66].
2. AAV Capsid Modification Strategies

2.1. Natural AAV Genetic Diversity

Naturally occurring AAV capsid amino acid diversity is a useful resource for variation of functional properties. Over 100 serotypes have been isolated from humans and non-human primates [16,67]. AAV capsid properties modulate tissue tropism (Table 1) and capsid diversity may improve immune evasion and tissue tropism properties.

Bats are a rich source of AAV genetic diversity [68,69] and may provide capsids with improved tropism and immune evasion properties. For example, bat AAV sequences have low capsid identity (<60%), reduced antibody neutralization profiles, and increased muscle to liver transduction ratios compared to primate AAVs [70]. Bat AAV10HB was chosen for additional structural studies, and divergent loop structures were observed between AAV2, AAV5, and AAV10HB. The β-barrel motifs of AAV2, AAV5, and AAV10HB are highly similar. The root-mean-square deviation (RMSD) between the Cα atoms of VP3 within the conserved β-barrel strands and α-helical region of AAV2, AAV5, and AAV10HB is ~0.5 Å. The local RMSD of the VR-II, VR-VIII, VR-IX, and HI loops is less than 2 Å whereas all other VR loops have a local RMSD greater than 2 Å. Neither A20 (AAV2-specific) or ADK5b (AAV5-specific) antibodies recognize 10HB [29]. Bat AAV10HB is the first and only non-primate AAV structure [29]. More comparisons structure–function are needed to deduce capsid residues responsible for antibody evasion. Bat AAVs can be used to illustrate potential strategies of improving vector immune evasion: (1) vectors based on capsids of AAVs from non-human hosts to which humans would be immune-naive; (2) rational engineering of chimera, replacing surface loops containing known human neutralizing immunogenic (NIm) sites with corresponding loops from non-human AAVs that are not cross-neutralized; (3) incorporation of the same non-human AAVs in the pool used for AAVDJ-like selection of new variant vectors [34]; or site-directed escape mutation of NIm sites as they are identified within capsid structures. Each of these capsid-modification strategies is further explored within the section.

wtAAV is constantly evolving and novel variants can be isolated from original cultures or after virus propagation. For example, AAV3 is closely related to AAV2 and both serotypes were isolated from humans [71]. A comparison of AAV2 and AAV3 DNA sequences revealed that they were distinct but closely related serotypes [72]. AAV3 was re-isolated from the original AAV3 wild-type virus stock and an additional isolate (AAV3B) was discovered. Sequencing revealed a difference of six amino acids [72,73]. Virus evolution during laboratory passaging might have been even more consequential for AAV2. Human AAV2 isolates typically do not attach to HSPG until after adaptation to cell culture [74,75]. More recent studies indicate AAV2 adaptation quickly yields subtypes with reduced liver tropism and increased glycan attachment or increased liver tropism and reduced glycan attachment [76]. Finally, advances in high throughput long-read sequencing provide opportunities to discover AAV capsids (e.g., AAVv66 from AAV2) from human tissues with unique tropism and antibody evasion properties [77]. Therefore, some natural AAV capsid diversity is potentially present in wild isolates, and AAV capsid differences can quickly emerge during laboratory propagation.

Paleovirology and AAV ancestral reconstruction approaches provide another means to harness natural AAV diversity. Viral genome integration occasionally occurs in animal germ cells, and these ancient insertion events are ubiquitous in extant animal genomes. The insertion events are referred to as “EVEs” (EVEs: Endogenous Viral Elements), and ancient AAV insertions are AAV-EVEs [78]. Comparisons of AAV-EVEs from sequenced mammalian host genomes provide estimates of divergence times based on the last common ancestors of EVE hosts. Current estimates suggest AAV integrated into mammalian genomes 23–77 millions of years ago (MYA) [78].

Capsid differences are observed between extant primate AAVs and ancient mammalian AAV-EVEs [78]. Some of the differences are found in the mammalian AAV-EVE VP1u domain. The AAV-EVE PLA2 domains have similar loss of function mutations but have intact calcium-binding sites [78]. Mutant PLA2 paired with functional calcium-
binding sites indicates a potential selective advantage for calcium-dependent functions with the concurrent absence or reduction of \( \text{PLA}_2 \) activity.

Exploration of intermediates between EVEs and AAVs can be further evaluated using ancestral sequence reconstruction (ASR) by phylogenetic analysis [79]. AAV ASR uses known AAV capsids to generate predicted ancestral capsid sequences with potentially beneficial attributes [80,81]. The primate AAV serotypes 1–3 and 7–9 are the primary focus of many clinical studies, and ASR identified a recent primate AAV ancestor, Anc80L65, as a novel vector with potentially valuable properties [80]. A phylogenetic tree was constructed using 75 primate AAV sequences along with predicted ancestors at each branch node. Based on its phylogenetic position, the Anc80 ancestor was chosen to create an Anc80 library (Anc80Lib) consisting of 776 clones representing the predicted amino acid variability at the Anc80 node. One clone, Anc80L65, was chosen for additional studies and showed increased transduction properties and reduced antibody neutralization. The utility of this approach is highlighted by the recent use of \( \text{rAnc80L65} \) to restore balance and hearing loss in neonatal and embryonic mouse models [82,83].

Interesting differences are also observed in the capsid residues of ASR AAV tree nodes. A homology model of the Anc80 node structure was created using the AAV8 crystal structure (PDB: 2QA0) [80]. The majority of predicted structural differences between AAV2, AAV8, and Anc80 are located near the 3-fold spikes [80]. Residue differences between Anc80, predicted AAV2 ancestral nodes, and AAV2 were superimposed on predicted T cell and antibody epitopes [84,85]. Capsid differences in the lineage leading to AAV2 tend to aggregate near predicted epitopes [80]. This evidence suggests a virus evolutionary model in which immune recognition significantly influences the evolutionary trajectory of primate AAVs.

Beyond sequence–structure variation within capsid subunits, another variable that can be modulated is the ratio of VP1-3. VP1 is important for cell transduction [86,87]. Wild-type AAV2 has a VP1-3 ratio of 1:1:10 [88,89], equating to about 3–6 VP1 monomers per capsid [90]. A modest decrease in VP1 levels is detrimental to cell transduction while an increase in VP1 levels and decrease in VP2 levels (VP1:VP2:VP3 equals 1.9:0.1:8) increases transduction [91]. Note that while overexpression of VP1 increases transduction, it also leads to reductions in \( \text{rAAV} \) yield [91]. The underlying mechanism is unknown, but reduced \( \text{rAAV} \) production might be associated with VP1u-associated protease activity and subsequent self-digestion or insufficient levels of VP2/3 for AAV packaging [91,92]. As for recombinant expression systems, one baculovirus system generates reduced levels of VP1 [93], but modifications can increase VP1 to wild-type (VP1 equals 10% of VP3) levels [94]. The published VP1 maximum is a VP1-3 ratio of 1.9:0.1:8 [91]. Optimized levels of VP1 may further improve \( \text{rAAV} \) transduction efficiency.

\( \text{AAV vector “pseudotyping”} \) is a well-established technique in which the genome of one virus is encased by a different serotype, a different virus or a synthetic virus [95]. AAV capsid monomers from different plasmid sources can also form “mosaic” \( \text{rAAV} \) particles with altered transduction efficiency. Mosaic \( \text{rAAV} \) are typically avoided for current gene therapy approaches [96], but researchers continue to identify mosaic AAV capsids with unique biochemical and transduction properties [97–101].

### 2.2. AAV Directed Evolution

Another AAV capsid modification strategy uses the power of directed evolution (Figure 3). Directed evolution uses artificial selection to engineer changed molecular phenotypes. RNA was the first target molecule of directed evolution [102] but this process has since then been applied to proteins [103–105] and protein enzymes [106]. The importance of directed evolution was recently recognized with the 2018 Nobel Prize in Chemistry [107].

\( \text{rAAV} \) capsids encode both enzymatic (e.g., VP1u \( \text{PLA}_2 \)) and structural properties vital for cell entry, and these properties can be improved via directed evolution. Directed evolution of protein sequences typically relies on “DNA shuffling” of the DNA encoding the protein [108,109]. DNA shuffling utilizes the power of recombination between similar
DNA sequences (i.e., homologous recombination) and can utilize fragmented DNA and/or PCR-based reassembly. Homologous recombination occurs naturally in parvovirus [110] and wtAAV populations [16] and is also observed in laboratory cultures of AAV-infected cells [111]. Following recombination, clonal isolates of AAV recombinants can be identified for further characterization [112].

Directed evolution of AAV capsids relies on large diverse AAV capsid DNA libraries to select candidate AAVs. Libraries are built using homologous recombination-based shuffling of selected parental AAV DNA. Error-prone PCR, with or without a staggered extension process, can be used to increase library genetic diversity [113–115]. Recombination can be further enhanced using capsid DNA sequences from closely related serotypes or codon-optimized capsids [116]. Optimized directed evolution pipelines generate DNA libraries with sufficient genetic diversity to select for infectious isolates [117]. Subpopulations can then be isolated using additional selection steps [117]. Selection schemes can be applied in vitro and/or in vivo to clone chimeric AAVs with favorable tropism, reduced immune neutralization, or desirable biochemical properties.

![Figure 3.](image-url) Capsid modification strategies. The three major approaches to capsid modifications are, from left to right: natural diversity (left dashed line box), directed evolution (middle), and mutants (right dashed line box). Natural primate AAV diversity includes the major and unique AAV clades. Directed evolution begins with parental serotypes, and these are diversified via recombination-based techniques (see text for details). This creates an AAV library that can be screened with selection of novel variants. Novel variants can then be amplified for additional rounds of selection or tested in animal models as a candidate rAAV biopharmaceutical. The mutants box consists of an AAV2 60-mer corresponding to Figure 2a at the top and a mutated yellow AAV2 60-mer at the bottom with mutations highlighted in red. The dashed-line circle surrounds the 3-fold axis, and a close-up view of this region is shown in the bottom right dashed box. Solid line circles show the peaks of each axis and the 3-fold depression is in the center. The three ~3.5 nm diameter red patches are “dead zones” first identified in Lochrie et al., 2006 [118]. Comparison of the top and middle models shows that the dead zone is mostly on a plateau between spikes where the PKD2 domain is bound in the AAV2-AAVR complex [119,120]. A summary of these mutations and others is provided in Supplementary Table S1. Structures were prepared using PyMOL [66].
A significant advance in tracking and evaluating large complex AAV capsid DNA libraries is the use of DNA barcodes (i.e., AAV barcode-Seq) [121]. DNA barcodes can be used to measure the fitness of mutations over time [122]. The combination of DNA barcodes and high-throughput sequencing provides additional means to identify variants from scanning libraries with favorable traits, such as tropism to particular tissues, in vivo [121,123,124]. Subsequent research has validated the use of barcodes as a standard approach to managing and tracking a wide range of AAV libraries [38,45,123–129].

Directed evolution approaches have yielded a number of chimeric AAV constructs that were subsequently developed as rAAV vectors, often with the goal of modulated tropism [34,130–132]. AAV-DJ is the most fully characterized and is a chimera of AAV2, AAV8, and AAV9 derived from the DNA shuffling of eight different AAV serotypes targeting human liver [34]. Hybrids of eight parental serotypes (AAV2, 4, 5, 8, 9, avian (bird) AAV, bovine (cow) AAV, and caprine (goat) AAV) were initially passaged through human liver cells leading to a more select population of hybrids in which only five serotypes were represented (2, 4, 5, 8, and 9). Following liver transduction, the population was further reduced to a single hybrid of three serotypes (2, 8, and 9) by selection for resistance to pooled neutralizing human antisera (intravenous immunoglobulin or IVIg) [34]. The AAV-DJ IVIg-escape variant differs from its closest single parent (AAV2) at 60/737 amino acids (~8.1%) [34]. AAV-DJ was the most efficient serotype for in vitro transduction of 15 cell lines from multiple tissues and species [34]. AAV8 and AAV9 are superior to AAV2 for liver transduction, and AAV-DJ was on par with AAV8/9 in vivo liver expression [34]. Gene therapy may require multiple doses, and an immune response typically neutralizes reinfusion of the primary vector. Prior use of AAV-DJ did not elicit a neutralizing immune response that was able to block subsequent transduction with rAAV2, rAAV8, or rAAV9. The most striking difference between AAV2 and AAV-DJ is observed at VR-I, which corresponds to the epitope of neutralizing mouse monoclonal antibody (mAb) A20 [30,133–135]. Therefore, AAV-DJ is a product of directed evolution with superior transduction and antibody evasion properties compared to its closest related ancestor (AAV2). It seems likely that rigorous selection for IVIg-escape generated change at a known neutralizing epitope, and this also affected cellular tropism [30].

A possible cautionary tale of the power of selection was the recent development of an AAV variant that can cross the blood–brain barrier (BBB). AAV9 had early promise as a treatment for CNS disorders because strong CNS expression was observed in small and large mammalian models [136–138] and AAV9 can pass through the mouse BBB but to a limited extent [136]. A novel Cre recombination-based AAV targeted evolution (CREATE) approach was developed to improve CNS transduction efficiency, and an AAV-PHP.B variant was identified [139]. CREATE utilizes libraries consisting of heptapeptide insertions into a permissive AAV9 site that corresponds with AAV2 glycan attachment (amino acids 588/589; Section 3.1). Intravenous administration of AAV-PHP.B showed promising transduction (~50-fold improvement) in the entire adult mouse CNS and abrogated the non-CNS expression that would have been expected of AAV9. Thus, the improved transduction efficiency of AAV-PHP.B in the CNS of a mouse model provided a promising lead for human CNS rAAV gene therapy.

A follow-up study showed, however, that AAV-PHP.B was specific to the C57BL/6j mice used for in vivo selection [140] and not BALB/cj mice. This observation quelled excitement over the potential translational use of AAV-PHP.B but provided the basis for mapping the LY6A genetic variants responsible for unlocking the C57BL/6j BBB [141]. LY6A is a GPI-anchored protein, and GPI-protein-mediated transport has been suggested as a determinant of AAV2 and AAV5 transduction [142,143]. Consequently, one could postulate that LY6A is an attachment factor or receptor that enables transport through the BBB. Meanwhile, another AAV9 variant (AAV-F) has been identified with superior CNS transduction properties using the iTransduce version of CREATE in the same permissive AAV9 site, and AAV-F does not utilize LY6A [144]. One lesson from AAV-PHP.B is that there is a danger of using (well-characterized) in-bred animal models to select viral vector traits
that are only compatible with host genotypes not found in human populations. Another lesson is further encouragement to modulate tropism by selection from a library in which peptide sequence is randomized locally at a site that is surface accessible in the structure and available to interact with host factors [139,145].

2.3. AAV Mutants

Early AAV capsid analyses were directed towards mapping epitopes and glycan attachment sites using peptide scanning (PEPSCAN), peptide competition, and site-directed mutation of recognizable sequence motifs [134,146–148]. The atomic structure of AAV2 [22] opened the way for more rational mutation analyses. For example, the AAV2 glycan attachment site was now clearly visible and, of the basic amino acids with potential to interact with heparan sulfate [36], five were now seen on the capsid exterior (See Section 3.1.1). The AAV2 structure provided the necessary details to interpret previous mutagenic studies and to move forward with structurally-informed screens.

A particularly noteworthy study by Lochrie et al. investigated several phenotypes, following systematic mutation that screened a wide area of the accessible outer surface of AAV2 [118]. Of 145 amino acids on the outside surface, 64 of the most exposed (~55% of surface area) were targeted as potential antibody-binding epitopes. The screen validated predicted basic amino acid residues responsible for heparin attachment. An additional circular area composed of eighteen amino acids (7 acidic and 1 basic) was also identified. Mutations in this ~3.5 nm diameter “dead zone” (Figure 3) decreased in vitro transduction independent of heparin-binding [118].

Antibody neutralization was also investigated. The mouse A20 antibody is well-known for AAV2 neutralizing activity, and a cluster was identified with five adjacent residues and one nearby as sites of neutralization of escape mutants. These mutants did not affect heparin attachment or transduction activity [118]. Similarly, three potential epitopes consisting of mutations that evaded three different samples of human sera from factor IX-deficient hemophiliacs were identified. One of these sites overlapped with the A20 epitope [118]. Finally, Lochrie et al. used human IgG (IVIg), pooled from >1000 individuals, to scan for additional epitopes. The suite of mutations responsible for AAV2 Nab evasion provides targets for stealth rAAV gene therapy vectors.

One exciting new addition to the AAV genetic manipulation toolkit utilizes a systematic approach to investigating AAV [38]. The entire capsid genome of AAV2 was modified, barcoded, and subjected to thermostability and transduction assays. The study confirmed the earlier observation [118] that the 3-fold spike is more tolerant of mutations compared to the 5-fold axis. Furthermore, by correctly identifying amino acids at the previously determined binding site of neutralizing antibody A20 [135], proof of principle was achieved that the approach could be used to map interaction sites.

The ability to monitor large AAV libraries also allows for improvements in rAAV capsid engineering via the design and implementation of computational models. Machine learning (ML) methods improve protein modeling and engineering [149], and the rational design of AAV capsids also benefits from ML. For example, a ML model was used to engineer AAV2 variants with superior liver transduction compared to AAV2 variants selected from randomly mutagenized populations [38]. Viable capsid formation is the first step of vector production, and ML models of capsid viability provide a useful measure of fitness. ML-based AAV libraries improved diversity in the 3-fold spike [128] and found unexpected differences in selection pressure for residues affecting capsid stability [150].

Another study started with electron microscopy imaging of AAV-antibody complexes, using pseudo-atomic models of multiple anti-AAV8 antibodies to identify important AAV8 epitopes at ~12–25 Å resolution [151]. AAV8 target residues were subjected to saturation mutagenesis, and the library was screened using human liver cells. A variant with improved transduction profiles and increased immune evasion was isolated, evidencing the utility of this approach [151]. Large AAV libraries engineered using computational
models are poised to produce rAAV vectors with improved rAAV capsid properties such as viability, tropism, thermostability, and antibody evasion.

3. AAV Cell Attachment and Entry

3.1. AAV Glycan Attachment Factors

3.1.1. HSPG

Extracellular glycans (e.g., glycoproteins, glycolipids) are common virus attachment factors and heparan sulfate proteoglycan (HSPG) attachment is used by several AAV serotypes prior to cell entry [54]. Heparan sulfate (HS) is a glycosaminoglycan that is covalently attached to protein. HS and heparin are negatively charged linear polysaccharides with heparin being the more sulfonated of the two forms. The most common disaccharide in HS (~50%) is glucuronic acid, linked to N-acetylglucosamine. HS and heparin interact with positively charged amino acids such as arginine and lysine [36,152]. Interactions of HS and heparin with proteins predominantly occur via electrostatic interactions with minor contributions from hydrogen bonds, hydrophobic effects and van der Waal interactions [153,154].

With the discovery of AAV2 HS-attachment [36], questions remained regarding the importance of HSPG in AAV infection. The 3.0 Å structure of AAV2 [22] and mutagenic studies [155,156] revealed the location of the AAV2 HSPG attachment site clustered on the side of each 3-fold spike (Table 2). The site was narrowed down to five basic amino acid residues responsible for HSPG-attachment (R484, R487, K532, R585, and R588) with the most severe loss of HSPG attachment occurring via R585 and R588 mutations in three major mutagenic studies [118,155,156]. The 8.0 Å cryo-EM structure of AAV2 complexed with heparin [133] confirmed the predicted HSPG attachment site derived from the AAV2 crystal structure [22]. Some of the positively charged residues responsible for AAV2 HSPG attachment (R585 and R588) are not conserved in other serotypes [133], which necessitated additional studies.

Table 2. Structures of AAV with Attachment Factors.

| Serotype | Resolution | Year | Reference |
|----------|------------|------|-----------|
| AAV2     | Cryo-EM 8.3 Å | 2009 | O’Donnell et al. [133] |
| AAV3     | X-ray 6.5 Å | 2012 | Lerch et al. [157] |
| AAV5     | X-ray 3.5 Å | 2015 | Afione et al. [158] |
| AAV1     | X-ray 3.0 Å | 2016 | Huang et al. [159] |
| AAVDJ    | Cryo-EM 3.0 Å | 2017 | Xie et al. [160] |

Follow-up structures of related serotypes indicated that the location of the AAV2 HSPG attachment site is not conserved across serotypes. AAV6 also attaches to HSPG and the 3.5 Å X-ray crystallography structure of AAV6 revealed a divergent but overlapping HSPG attachment site confirmed via site-directed mutagenesis [26]. AAV6 is missing the positively charged AAV2 R585 and R588 residues but compensates with two positively charged lysines at a different location (K459 and K493). Preliminary evidence suggested the AAV2 and AAV6 sites were more similar to each other compared to AAV2 and AAV3B HSPG attachment sites [23]. AAV3B is closely related to AAV2 and both serotypes were isolated from humans [71]. AAV3B also attaches to HSPG [97,161], but AAV3B lacks the AAV2 residues with the strongest interactions: R585 and R588. Other AAV3B residues could be postulated to fulfil an analogous role (R447 and R594). AAV3B was complexed with the sucrose octasulfate (SOS) heparin analog to generate a 6.5 Å X-ray crystallographic structure with sufficient resolution to identify the binding site which was on a 3-fold axis, where three copies of R594 come together [157]. In the cases of AAV2 and AAV3B, it was shown, through chimeric mutation, that electrostatic potential contributed by different amino acids was additive in its effects upon heparin-binding, cell binding, and in vitro cell transduction [157]. Thus, while binding using analogous interactions, the sites on AAV2
and AAV3B do not correspond. Therefore, AAV HSPG attachment sites exhibit convergent evolution with selection of positively charged residues.

Aware that at some point, conformational changes would be needed for the release of VP1u and DNA, one question was whether glycan-binding induced the presumed changes [162]. Such speculation was inspired by other viruses; for example, the attachment of HIV to heparin sulfate and subsequent conformational changes are critical components of HIV co-receptor binding [163]. The 8.3 Å cryo-EM structure of a 17 kDa heparin fragment (~70 monosaccharide units; ~285 Å long) complexed with AAV2 revealed heparin wound around the shoulders of the 3-fold protrusions, bound by interactions of its sulfate groups with basic arginines and other polar interactions [133]. However, conformational adjustments were very modest and local to the binding site—there was no indication of a capsid-opening conformational change.

Belief in large-scale glycan-induced conformational change persisted due to hints thereof in an independently determined structure of an AAV2-heparin complex at 18 Å resolution [162]. At the low resolutions of both studies, there is increased danger of mis-characterization, so the difference could not be adjudicated immediately. Subsequently, to be more definitive, AAV-DJ [30,34], which shares an AAV2-like HBD, was used for cryo-EM of an SOS complex at 4.8 Å resolution [164] and for a complex with a synthetic pentasaccharide heparin analog, fondaparinux at 2.8 Å resolution [160]. The cryo-EM maps were much improved, due to chemical homogeneity of the HS analogs and improving EM technology. It was now seen that the AAV structure could make local adaptations to different glycan sequences, but that no large-scale changes were induced by binding. Indeed, evidence was also emerging through competition surface plasmon resonance (SPR) and glycan arrays that the glycan sequence specificity was quite low and that high avidity was achieved with longer heparin oligosaccharides that could bridge between symmetry-related binding sites, combining the affinities thereof [93,165]. The combined evidence implies AAV HSPG attachment is a product of multiple weak-avidity sites on a single capsid. The locations of HSPG attachment can vary between serotypes, and HSPG attachment can be rapidly selected for or against in the laboratory environment.

3.1.2. SIA and GAL

Sialic acid (SIA) was the first virus receptor to be discovered [166,167] and serves as a receptor or attachment factor for many viruses. SIAs are a diverse group of nine-carbon sugars that attach to the end of O-linked (serine or threonine) or N-linked (asparagine) sugar chains. Coronavirus, influenza, and other zoonotic viruses use glycan oligosaccharides terminated in SIA for cellular entry, and SIA may play an important role in crossing species barriers [168]. In paroviruses, SIA attachment determines MVM tropism and pathogenicity [169] whereas CPV and FPV SIA attachment is not required for infection [170].

O-linked and N-linked SIA have been reported as receptors for several AAVs, although, like HS, SIA should now, more properly, be considered an attachment factor (vide infra). Glycan-conjugated SIA is known to interact with AAV1, AAV4, AAV5, and AAV6 [171,172]. AAV4 attaches to α2,3 SIA on O-linked oligosaccharides whereas AAV5 attaches to α2,3 SIA on N-linked oligosaccharides [171]. On the other hand, AAV1 and AAV6 use both α2,3 and α2,6 SIA on N-linked oligosaccharides for cellular attachment [172]. The 3.5 Å X-ray crystallographic structure of SIA-bound AAV5 was examined, and two candidate sites (A and B) were used as a foundation for site-directed mutagenesis [158]. Mutations to residues in the A site were responsible for N-linked SIA attachment. The X-ray crystallography structures of AAV1 and AAV6 revealed additional N-linked SIA attachment areas consisting of six amino acids [159]. Similar to HSPG attachment sites, SIA attachment sites are not conserved and the mutation of residues identified by X-ray crystallography ablate glycan attachment.

AAV9 is unique in that it has a preference for glycans ending in a terminal galactose (GAL) [173]. Mutational studies and computer modeling of docked structures implicate a patch of residues at the base of the 3-fold axis protrusions [174]. This site is distinct from
the HS and SIA sites of other AAVs and further emphasized that, among AAVs, divergent strategies have evolved for the attachment to cell surface glycans.

3.2. AAV Proteinaceous Receptors

3.2.1. AAVR

A variety of possible co-receptors proteins have been reported over the years. For example, the hepatocyte growth factor receptor (c-MET) and human fibroblast growth factor receptor-1 (FGFR1) were identified as possible protein co-receptors for AAV2 [175,176]. Platelet-derived growth factor receptor (PDGFR) is a candidate receptor for AAV5 [177] while epidermal growth factor receptor (EGFR) was identified as a candidate receptor for AAV6 [178]. A report identifying α5β5 integrin as an AAV2 co-receptor [179] was contested by another study [180]. Other proposed receptors included integrin α5β1 [181], LamR for a variety of serotypes [182], and an unidentified 150 kDa glycoprotein [183]. The candidate ~150 kDa protein could be qualitatively observed using virus overlay assays and binding was quantified using cell culture binding assays. Cell-binding could be ablated by trypsinization, with a time-dependent recovery that suggested the involvement of a protein with an eight-hour turnover [183]. The identity of the 150 kDa protein receptor responsible for wtAAV2 binding would remain a mystery for two decades.

Convincing evidence of a cellular entry receptor was eventually found using a high-throughput forward genetic screen to identify conclusively genes involved in AAV transduction [37]. Keys to successful screening were a nearly haploid human cell line (HAP1), a retrovirus gene-trap used to mutagenize most non-essential genes [184], and, because AAV is not cytopathic, methods for iteratively selecting viral resistance based on fluorescence-encoding viral vectors and cell sorting. Then, using an AAV2 vector encoding RFP, repeated fluorescence-activated cell sorting (FACS) cycles were used to select a cell population enriched in AAV-resistant (RFP-negative) mutants. Deep sequencing of cells yielded a list of 46 genes that were mutated with statistically significant frequencies. These could be grouped into genes encoding proteins involved in trans-Golgi network trafficking, heparan sulfate synthesis, a handful of “other” hits and three genes encoding transmembrane proteins. The three transmembrane proteins (KIAA0319L, GPR108, and TM9SF2) were relatively uncharacterized and had not been previously implicated as viral entry factors. The gene candidate with the highest significance (570 independent mutations) was a type I transmembrane protein known as KIAA0319L and was subsequently renamed to AAV Receptor (AAVR).

CRISPR-Cas9 was used to create knockouts (KO) of AAVR in eight diverse human and mouse cell lines and TALENs were used to create AAVRKO mice [37]. The AAVRKO cell lines were resistant to infection with AAV2, even at high doses of 100,000 viral genomes per cell. Infectivity could be restored in AAVRKO cells by expressing AAVR and overexpression of AAVR in cell lines resistant to AAV2 infection rendered the cells permissive to AAV2 infection [37]. AAV2 infection was inhibited via the introduction of soluble AAVR ectodomain or antibodies against AAVR, thereby highlighting the potential importance of access to AAVR on the cell surface. Several other human and simian serotypes (AAV1, 2, 3B, 5, 6, 8 and 9), with preferences for diverse glycan attachment factors, were also unable to infect AAVRKO cells, but could infect cells rescued with AAVR. Similarly, another study found overexpression of AAVR in polarized epithelial cells generates preferentially basolateral localization of AAVR and increased transduction of AAV2 on the basolateral side [185]. In contrast, CRISPR-Cas9 KO of two of the top previously-implicated AAV2 candidate co-receptors (c-MET and FGFR1), in several cell lines, did not decrease transduction efficiency [37]. These results highlighted the importance of AAVR as a primary cell entry receptor for AAV2 and suggested other previously identified AAV2 candidate receptors may play, at most, accessory roles.

The dependence of AAV2 on AAVR for infection warranted further investigations into the protein domains controlling infection. AAVR is an N-linked and O-linked glycoprotein that can be subdivided into three regions: an N-terminal motif with eight cysteines
(MANEC domain), five immunoglobulin-like polycystic kidney disease (PKD) domains (PKD1-PKD5) and a C-terminal transmembrane region (Figure 4a). AAVR proved to be the same as the previously implicated but unidentified ~150 kDa glycoprotein [183,186], although it became clear that the ~50 kDa glycosyl moieties were not required for AAV2 infection [186]. AAVR was found to colocalize with TGN components, as does AAV2 when trafficking from the plasma membrane through endosome compartments to the Golgi [142,186]. Removal of the AAVR C-terminal domain, which contains endosome targeting motifs, prevented rescue of AAVRKO cells and impaired endocytic recycling; resulting in increased AAVR localization to the plasma membrane [186]. The PKD domains of AAVR have immunoglobulin-like (Ig-like) folds that are common in viral receptors [187]. A soluble ecto-domain construct, containing PKD1-5 domains was able to bind AAV2 particles, and a mini-AAVR construct consisting of PKD1-3 together with the transmembrane moiety was sufficient to rescue AAVKO cells [37]. Further analysis with both domain expression constructs and domain deletion mutants that, for AAV1, AAV2 and AAV8, there were strong interactions with PKD2, and subsidiary involvement of PKD1 [186]. By contrast, AAV5 primarily utilizes PKD1, apparently exclusively [186]. The amino acids responsible for AAV-AAVR interactions were soon revealed in a series of structural studies (Table 3; Figure 4b,c) [119,120,188,189]. The footprint of AAV2:PKD2 was found to overlap with a significant fraction (39–56%) of the eighteen residues comprising the previously identified dead zone [118–120]. The overlapping footprints of AAVR and antibodies provide additional insights into AAV-antibody neutralizing and cell entry mechanisms.

| Serotype | Resolution | Year | Reference | PDBid |
|----------|------------|------|-----------|-------|
| AAV1     | Cryo-EM 3.3 Å | 2019 | Zhang et al. [189] | 6JCQ |
| AAV2     | Cryo-EM 2.8 Å | 2019 | Zhang et al. [120] | 6IHB |
| AAV2     | Cryo-EM 2.4 Å | 2019 | Meyer et al. [118] | 6NZO |
| AAV5     | Cryo-EM 3.2 Å | 2019 | Zhang et al. [189] | 6JCS |
| AAV5     | Cryo-EM 2.5 Å | 2020 | Silveria et al. [188] | 7KPN |

3.2.2. GPR108 and VP1u

In addition to AAVR-dependent serotypes, at least one primate AAV lineage does not require AAVR for cell transduction and multiple serotypes still exhibit low levels of transduction in the absence of AAVR. Anc80 is predicted (in silico) to be ancestral to AAV2 (Section 2.1) and this lineage is typified by PKD2 binding whereas the lineage leading to AAV5 binds to PKD1. The lineage leading to AAV4 and AAVrh32.33, on the other hand, is AAVR-independent [190]. Anc80 and its descendants also exhibited low levels of AAVR independence whereas AAV5 is solely dependent upon AAVR for cell transduction [190].

Two independent screens validated the Pillay et al. screen hit GPR108 (i.e., Lung Seven Transmembrane Receptor2; LUSTR2) as an important factor for AAV transduction [191,192]. GPR108 is a seven-transmembrane protein with a long N-terminal lumen domain and a short C-terminal domain essential for AAV transduction [191]. Representative members of the Anc80 lineage are dependent on both GPR108 and AAVR whereas the AAV4 clade is mostly dependent just on GPR108 and does not require AAVR for entry [191]. AAV5 does not require GPR108 and the VP1u region of AAV2 can transfer GPR108 dependence to AAV5 [191]. Furthermore, GPR108 expression overlaps with AAVR expression in the TGN [191,192]. Of several possible explanations of the observations, one is that attachment of AAV2-like viruses to HSPG is followed by binding to AAVR, and eventual VP1u extrusion for a GPR108-mediated step in the TGN (Figure 5b) [191].
Figure 4. AAV2 and AAV5 bind to distinct AAVR PKD domains. (a) AAVR domain structure from N-terminus (N) to C-terminus (C): Signal Peptide (SP), Motif At the N-terminus with Eight Cysteines (MANEC), immunoglobulin-like Poly-cystic Kidney Disease (PKD) domains 1–5, TransMembrane (TM) helix and Cytoplasmic domain (Cyto). The region containing potential AAV interactions is composed of PKD1-5. (b) Native AAV2 60-mer (left) and the AAV2:PKD2 complex (right). Virus models are colored by radial distance from the center of the virion. The PKD2 domain of AAVR is colored in gray. (c) Virus model of native AAV5 virion (left) and the AAV5:PKD1 complex (right). Models are colored by radial distance from the center of the virion. The PKD1 domain of AAVR is colored in gray. Structures in (b,c) were prepared using PyMOL [66].
Figure 5. AAV entry model. (a) Three known AAV entry classes are shown: AAVR-dependent (green star), GPR108-dependent (light blue box) and both AAVR and GPR108-dependent (black asterisk). Structures for AAV complexes with glycan attachment factors (yellow and red circles) and AAV:AAVR complexes (light blue receptor icon) are known. Appropriate AAV entry class icons are located to the left of AAV serotypes and structural icons are located to the right of AAV serotypes with structural evidence. (b) AAV cell attachment, entry, and trafficking to the nucleus of a non-polarized cell. Two AAV classes are shown: AAVR/GPR108-dependent (red; majority of AAVs), represented by AAV2, and GPR108-dependent/AAVR-independent (blue; AAV4 clade). Virions must evade host neutralizing antibodies (black antibody-shaped icons). AAV virions (red or blue) come into contact with the cell surface and attach to the glycan moieties of proteoglycans. Red AAV binds to the AAVR receptor and is internalized and transported through the trans-Golgi network (TGN). Blue, GPR108-dependent, AAV particles enter through a parallel but possibly distinct pathway. Virions accumulate outside of the nucleus before entry and may involve the nuclear pore complex (NPC). AAV gathers in the nucleolus prior to being extruded into the nucleoplasm where the ssDNA genome is released.
AAV cellular entry screens are offering insights that are likely relevant to release of VP1u. Both AAVR and GPR108 are predicted transmembrane proteins found in the TGN. Other hits of the forward genetic screens include genes implicated in glycan biosynthesis and TGN functions. One TGN gene high on the list of genes identified by Pillay et al. is ATP2C1. This gene encodes a secretory pathway Ca(2+)−ATPase pump type 1 (SPCA1) important for sequestering calcium ions into the Golgi compartment from the cytosol and also for Golgi ribbon maintenance [193]. AAV conformational changes associated with VP1u extrusion are affected by increased cytosolic calcium levels in ATP2C1 KO cells [194]. The VP1u phospholipase is calcium-dependent [195] and can be induced to extrude by heating from 37 °C to 65 °C [196]. VP1u protease activity that targets disordered proteins has also been detected [197]. Further characterization of genes underlying VP1u-associated effects may provide a roadmap for future mechanistic studies of AAV cellular entry.

4. Concluding Remarks

The number of rAAV gene therapy options continues to grow. In addition, advances in structural biology provide easier access to molecular details responsible for cell entry and escape from neutralizing antibodies. Such details are beginning to help investigators design increasingly sophisticated capsid modification schemes to improve rAAV vector properties. Much remains to be learned about the key molecular interactions of capsid with host factors, and one would anticipate continuing feedback into vector design over the coming years. There are also areas in which the salient molecular interactions remain largely uncharacterized, such as cellular immune responses, and so progress in vector delivery, at the moment, involves empirical mitigation strategies [35,198].

Particularly exciting, is the more detailed picture of rAAV cellular entry mechanisms that is now emerging. The discovery of AAVR and the resultant AAV-AAVR structures reveal important capsid surface moieties responsible for cell entry. The AAV4 clade primarily uses AAVR-independent mechanisms for cellular entry, and these insights apply to multiple serotypes, with the possible exception of the AAV5 clade. Further characterization of GPR108-mediated cell entry may provide additional tools for rAAV gene therapy improvement. It is important to emphasize that identification of the most critical host factors for entry is recent, their characterization is ongoing, and exploitation of the emerging understanding for improved vector delivery is only just starting.

That said, our changed perspective on the role of extracellular glycans might be equally important. Designated as primary receptors, there was naturally much attention on understanding the molecular basis of interactions and any specificity thereof that could possibly be exploited for targeting, but we now understand that specificity is less than exquisite [93,165]. Real glycan-dependent tropisms, in vivo, could have a variety of non-receptor-mediated explanations, as are now being uncovered. These can include glycan-dependent sequestration at a target site of interest [199] or rate of blood clearance [121]. Glycan interactions certainly continue to be important in vector optimization [76], but the design considerations may be quite different from modulation of cellular entry. Our newer perspective does not negate the long history of evidence, from in vitro assays, that glycans also mediate attachment to infected cells and thereby affect levels of transduction [36], albeit somewhat less critically than protein receptors [37]. However, now the process should be imagined, as in Figure 5b, with glycan attachment concentrating virus at the cell surface with high-valence modest-specificity interactions, common in many other viral families, improving the efficiency of binding to membrane proteins essential for entry and trafficking [200,201]. In overlapping but different ways, both glycan and protein interactions will be important in the development of more efficient and specifically targeted vectors.

The initial steps leading to AAV cellular entry are clearer, but important details remain unanswered. For example, questions addressing the tendency of AAV to bind AAVR more at the surface or in the endosome and the role of candidate co-receptor interactions with AAV remain unresolved. The subsequent function of AAVR in cellular
trafficking and potential roles for AAVR or co-receptors in the steps leading to capsid conformational changes preceding endosomal escape also remain inconclusive. Future studies may accurately resolve these important open questions, in light of our current understanding of AAV:AAVR interactions, with an eye on developing more potent rAAV gene therapy vectors.

**Supplementary Materials:** The following are available online at https://www.mdpi.com/article/10.3390/v13071336/s1. Supplementary Table S1: AAV Mutant Transduction Table. Supplementary Table S2: AAV Tropism Tables.

**Author Contributions:** Conceptualization, M.S.C.; writing—original draft preparation, E.E.L., M.A.S., G.M.Z., O.W. and M.S.C.; writing—review and editing, E.E.L., M.A.S., G.M.Z. and M.S.C.; supervision, M.S.C.; project administration, M.S.C.; funding acquisition, M.S.C. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by The National Institute of Health (NIH), R35 GM1222564.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Srivastava, A.; Weitzman, M.; Chatterjee, S.; Engelhardt, J.F.; Owens, R.A.; Muzykczka, N.; Ali, R. A Tribute to Barrie J. Carter. *Hum. Gene Ther.* 2020, 31, 491–493. [CrossRef] [PubMed]
2. Berns, K.I.; Muzykczka, N. AAV: An Overview of Unanswered Questions. *Hum. Gene Ther.* 2017, 28, 308–313. [CrossRef]
3. Meier, A.F.; Fraefel, C.; Seyffert, M. The Interplay between Adeno-Associated Virus and its Helper Viruses. *Viruses* 2020, 12, 662. [CrossRef] [PubMed]
4. Smalley, E. First AAV gene therapy poised for landmark approval. *Nat. Biotechnol.* 2017, 35, 998–999. [CrossRef] [PubMed]
5. Al-Zaidy, S.; Pickard, A.S.; Kotha, K.; Alfano, L.N.; Lowes, L.; Paul, G.; Church, K.; Lehman, K.; Sproule, D.M.; Dabbous, O.; et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. *Pediatr. Pulmonol.* 2019, 54, 179–185. [CrossRef]
6. Mendell, J.R.; Al-Zaidy, S.A.; Rodino-Klapac, L.R.; Goodspeed, K.; Gray, S.J.; Kay, C.N.; Boye, S.L.; Boye, S.E.; George, L.A.; Salabaria, S.; et al. Current Clinical Applications of In Vivo Gene Therapy with AAVs. *Mol. Ther.* 2021, 29, 464–488. [CrossRef]
7. Greer, C.; Kozyak, B.; Stedman, H. Challenges at the Crossroads: Myopathy Trials in 2020 Hindsight. *Mol. Ther.* 2021, 29, 420–421. [CrossRef]
8. Vandendriessche, T.; Thorrez, L.; Acosta-Sanchez, A.; Petrus, I.; Wang, L.; Ma, L.; Waele, L.D.E.; Iwasaki, Y.; Gillijns, V.; Wilson, J.M.; et al. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. *J. Thromb. Haemost.* 2007, 5, 16–24. [CrossRef]
9. Zais, A.K.; Liu, Q.; Bowen, G.P.; Wong, N.C.; Bartlett, J.S.; Muruve, D.A. Differential activation of innate immune responses by adenoovirus and adeno-associated virus vectors. *J. Virol.* 2002, 76, 4580–4590. [CrossRef]
10. Ferrari, F.K.; Xiao, X.; McCarty, D.; Samulski, R.J. New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors. *Nat. Med.* 1997, 3, 1295–1297. [CrossRef]
11. Matsushita, T.; Elliger, S.; Elliger, C.; Podsakoff, G.; Villarreal, L.; Kurtzman, G.J.; Iwaki, Y.; Colosi, P. Adeno-associated virus vectors can be efficiently produced without helper virus. *Gene Ther.* 1998, 5, 938–945. [CrossRef] [PubMed]
12. Xiao, X. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenoovirus. *J. Virol.* 1998, 72, 2224–2232. [CrossRef] [PubMed]
13. Grimm, D.; Kern, A.; Rittner, K.; Kleinschmidt, J.A. Novel tools for production and purification of recombinant adenoassociated virus vectors. *Hum. Gene Ther.* 1998, 9, 2745–2760. [CrossRef]
14. Clement, N.; Grieger, J.C. Manufacturing of recombinant adeno-associated viral vectors for clinical trials. *Mol. Ther. Methods Clin. Dec.* 2016, 3, 16002. [CrossRef] [PubMed]
15. Gao, K.; Li, M.; Zhong, L.; Su, Q.; Li, J.; Li, S.; He, R.; Zhang, Y.; Hendricks, G.; Wang, J. Empty virions in AAV8 vector preparations reduce transduction efficiency and may cause total viral particle dose-limiting side effects. *Mol. Ther.-Methods Clin. Dec.* 2014, 1, 9. [CrossRef]
16. Gao, G.; Vandenberghe, L.H.; Alvira, M.R.; Lu, Y.; Calcedo, R.; Zhou, X.; Wilson, J.M. Clades of Adeno-associated viruses are widely disseminated in human tissues. *J. Virol.* 2004, 78, 6381–6388. [CrossRef]
17. Schmidt, M.; Govindasamy, L.; Afione, S.; Kaludov, N.; Agbandje-McKenna, M.; Chiorini, J.A. Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). *J. Virol.* 2008, 82, 8911–8916. [CrossRef] [PubMed]
18. Schmidt, M.; Voutetakis, A.; Afione, S.; Zheng, C.; Mandikian, D.; Chiorini, J.A. Adeno-associated virus type 12 (AAV12): A novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. *J. Virol.* 2008, 82, 1399–1406. [CrossRef] [PubMed]
19. Mori, S.; Takeuchi, T.; Enomoto, Y.; Kondo, K.; Sato, K.; Ono, F.; Sata, T.; Kanda, T. Tissue distribution of cynomolgus adeno-associated viruses AAV10, AAVV1, and AAVVcy.7 in naturally infected monkeys. *Arch. Virol.* 2008, 153, 375–380. [CrossRef]

20. Mietzsch, M.; Jose, A.; Chipman, P.; Bhattacharya, N.; Daneshparvar, N.; McKenna, R.; Agbandje-McKenna, M. Completion of the AAV Structural Atlas: Serotype Capsid Structures Reveals Clade-Specific Features. *Viruses* 2021, 13, 101. [CrossRef]

21. Ng, R.; Govindasamy, L.; Gurda, B.L.; McKenna, R.; Kozyreva, O.G.; Samulski, R.J.; Parent, K.N.; Baker, T.S.; Agbandje-McKenna, M. Structural characterization of the dual glycan binding adeno-associated virus serotype 6. *J. Virol.* 2010, 84, 12945–12957. [CrossRef]

22. Xie, Q.; Bu, W.; Bhatia, S.; Hare, J.; Somasundaram, T.; Azzi, A.; Chapman, M.S. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. *Proc. Natl. Acad. Sci. USA* 2002, 99, 10405–10410. [CrossRef] [PubMed]

23. Lerch, T.F.; Xie, Q.; Chapman, M.S. The structure of adeno-associated virus serotype 3B (AAV-3B): Insights into receptor binding and immune evasion. *Virology* 2010, 403, 26–36. [CrossRef] [PubMed]

24. Govindasamy, L.; Padron, E.; McKenna, R.; Muzyczka, N.; Kaludov, N.; Chiorini, J.A.; Agbandje-McKenna, M. Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. *J. Virol.* 2006, 80, 11556–11570. [CrossRef]

25. Govindasamy, L.; DiMattia, M.A.; Gurda, B.L.; Halder, S.; McKenna, R.; Chiorini, J.A.; Muzyczka, N.; Zolotukhin, S.; Agbandje-McKenna, M. Structural insights into adeno-associated virus serotype 5. *J. Virol.* 2013, 87, 11187–11199. [CrossRef]

26. Xie, Q.; Lerch, T.F.; Meyer, N.L.; Chapman, M.S. Structure-function analysis of receptor-binding in adeno-associated virus serotype 6 (AAV-6). *Virology* 2011, 420, 10–19. [CrossRef] [PubMed]

27. Nam, H.J.; Lane, M.D.; Padron, E.; Gurda, B.; McKenna, R.; Kohlbrenner, E.; Aslanidi, G.; Byrne, B.; Muzyczka, N.; Zolotukhin, S.; et al. Structure of adeno-associated virus serotype 8, a gene therapy vector. *J. Virol.* 2007, 81, 12260–12271. [CrossRef]

28. DiMattia, M.A.; Nam, H.J.; Van Vliet, K.; Mitchell, M.; Bennett, A.; Gurda, B.L.; McKenna, R.; Olson, N.H.; Sinkovits, R.S.; Potter, M.; et al. Structural insight into the unique properties of adeno-associated virus serotype 9. *J. Virol.* 2012, 86, 6947–6958. [CrossRef]

29. Mietzsch, M.; Barnes, C.; Hull, J.A.; Chipman, P.; Xie, J.; Bhattacharya, N.; Sousa, D.; McKenna, R.; Gao, G.; Agbandje-McKenna, M. Comparative Analysis of the Capsid Structures of AAVrh.10, AAVrh.39, and AAV8. *J. Virol.* 2020, 94. [CrossRef] [PubMed]

30. Lerch, T.F.; O’Donnell, J.K.; Meyer, N.L.; Xie, Q.; Taylor, K.A.; Stagg, S.M.; Chapman, M.S. Structure of AAV-DJ, a retargeted gene therapy vector: Cryo-electron microscopy at 4.5 Å resolution. *Structure* 2012, 20, 1310–1320. [CrossRef]

31. Xie, Q.; Yoshioka, C.K.; Chapman, M.S. Adeno-Associated Virus (AAV-DJ)-Cryo-EM Structure at 1.56 A Resolution. *Viruses* 2020, 12, 1194. [CrossRef]

32. Li, C.; Samulski, R.J. Engineering adeno-associated virus vectors for gene therapy. *Nat. Rev. Genet.* 2020, 21, 255–272. [CrossRef] [PubMed]

33. Ellis, B.L.; Hirsch, M.L.; Barker, J.C.; Connelly, J.P.; Steininger, R.J., 3rd; Porteus, M.H. A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype. *J. Virol.* 2013, 87, 11187–11199. [CrossRef]

34. Grimm, D.; Lee, J.S.; Wang, L.; Desai, T.; Akache, B.; Storm, T.A.; Kay, M.A. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. *J. Virol.* 2008, 82, 5887–5911. [CrossRef]

35. Ronzitti, G.; Gross, D.-A.; Mingozzi, F. Human Immune Responses to Adeno-Associated Virus (AAV) Vectors. *Front. Immunol.* 2020, 11. [CrossRef] [PubMed]

36. Summerford, C.; Samulski, R.J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. *J. Virol.* 1998, 72, 1438–1445. [CrossRef]

37. Pillay, S.; Meyer, N.L.; Puschnik, A.S.; Davulcu, O.; Diep, J.; Ishikawa, Y.; Jae, L.T.; Wosen, J.E.; Chapman, M.S.; et al. An essential receptor for adeno-associated virus infection. *Virology* 2020, 6947–6958. [CrossRef] [PubMed]

38. Ogden, P.J.; Kelsic, E.D.; Sinai, S.; Church, G.M. Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design. *Science* 2019, 366, 1139–1143. [CrossRef]

39. Im, D.S.; Muzyczka, N. Partial purification of adeno-associated virus Rep78, Rep52, and Rep40 and their biochemical characterization. *J. Virol.* 1992, 66, 1119–1128. [CrossRef] [PubMed]

40. King, J.A.; Dubielzig, R.; Grimm, D.; Kleinschmidt, J.A. DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. *EMBO J.* 2001, 20, 3282–3291. [CrossRef]

41. Girod, A.; Wobus, C.E.; Zadori, Z.; Ried, M.; Leike, K.; Tijssen, P.; Kleinschmidt, J.A.; Hallek, M. The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. *J. Gen. Virol.* 2002, 83, 973–978. [CrossRef]

42. Maurer, A.C.; Cepeda Diaz, A.K.; Vandenbergha, L.H. Residues on Adeno-associated Virus Capsid Lumen Dictate Interactions and Compatibility with the Assembly-Activating Protein. *J. Virol.* 2019, 93. [CrossRef] [PubMed]

43. Sonntag, F.; Köther, K.; Schmidt, K.; Weghofer, M.; Raupp, C.; Nieto, K.; Kuck, A.; Gerlach, B.; Böttcher, B.; Müller, O.J.; et al. The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes. *J. Virol.* 2011, 85, 12686–12697. [CrossRef] [PubMed]

44. Naumer, M.; Sonntag, F.; Schmidt, K.; Nieto, K.; Panke, C.; Davey, N.E.; Popa-Wagner, R.; Kleinschmidt, J.A. Properties of the adeno-associated virus assembly-activating protein. *J. Virol.* 2012, 86, 13038–13048. [CrossRef] [PubMed]
20 of 25

Viruses 2021, 13, 1336

45. Earley, L.F.; Powers, J.M.; Adachi, K.; Baumgart, J.T.; Meyer, N.L.; Xie, Q.; Chapman, M.S.; Nakai, H. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of AAV Serotypes 4, 5, and 11. *J. Virol.* 2017, 91, e01980-16. [CrossRef]

46. Tse, L.V.; Moller-Tank, S.; Meganck, R.M.; Asokan, A. Mapping and Engineering Functional Domains of the Assembly-Activating Protein of Adeno-associated Viruses. *J. Virol.* 2018, 92. [CrossRef] [PubMed]

47. Maurer, A.C.; Facouret, S.; Cepeda Díaz, A.K.; Blake, J.; Andres-Mateos, E.; Vandenberghe, L.H. The Assembly-Activating Protein Promotes Stability and Interactions between AAV’s Viral Proteins to Nucleate Capsid Assembly. *Cell Rep.* 2018, 23, 1817–1830. [CrossRef]

48. Stutikka, C.; Gogol-Döring, A.; Botschen, L.; Mietzsch, M.; Weger, S.; Feldkamp, M.; Chen, W.; Heilbronn, R. A Comprehensive RNA Sequencing Analysis of the Adeno-Associated Virus (AAV) Type 2 Transcriptome Reveals Novel AAV Transcripts, Splice Variants, and Derived Proteins. *J. Virol.* 2016, 90, 1278–1289. [CrossRef]

49. Cao, M.; Chiriva-Internati, M.; Hermonat, P.L. AAV2 X increases AAV6 rep/cap-driven rAAV production. *Virology* 2015, 482, 84–88. [CrossRef] [PubMed]

50. Cao, M.; You, H.; Hermonat, P.L. The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. *PloS ONE* 2014, 9, e104596. [CrossRef]

51. Grieger, J.C.; Snowdy, S.; Samulski, R.J. Separate basic region motifs within the adeno-associated virus capsid proteins are essential for infectivity and assembly. *J. Virol.* 2006, 80, 5199–5210. [CrossRef]

52. Dennis, E.A.; Cao, J.; Hsu, Y.H.; Magriotti, V.; Kokotos, G. Phospholipase A2 enzymes: Physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. *Chem. Rev.* 2011, 111, 6130–6185. [CrossRef] [PubMed]

53. Zadori, Z.; Szefei, J.; Lacoste, M.C.; Li, Y.; Gariepy, S.; Raymond, P.; Allaire, M.; Nabi, I.R.; Tijssen, P. A viral phospholipase A2 is required for parvovirus infectivity. *Dev. Cell* 2001, 1, 291–302. [CrossRef]

54. Zengel, J.; Carette, J.E. Structural and cellular biology of adeno-associated virus attachment and entry. *Adv. Virus Res.* 2020, 106, 39–84. [CrossRef]

55. Rossmann, M.G. Structure of viruses: A short history. *Q. Rev. Biophys.* 2013, 46, 133–180. [CrossRef] [PubMed]

56. Rossmann, M.G.; Johnson, J.E. Icosahedral RNA Virus Structure. *Ann. Rev. Biochem.* 1989, 58, 533–573. [CrossRef]

57. Chapman, M.S.; Liljas, L. Structural folds of viral proteins. *Adv. Protein Chem.* 1993, 46, 125–196. [CrossRef] [PubMed]

58. Tsao, J.; Chapman, M.S.; Agbandje, M.; Keller, W.; Smith, K.; Wu, H.; Luo, M.; Smith, T.J.; Rossmann, M.G.; Compan, R.W.; et al. The three-dimensional structure of canine parvovirus and its functional implications. *Science* 1991, 251, 1456–1464. [CrossRef]

59. Penzes, J.J.; Soderlund-Venermo, M.; Canuti, M.; Eis-Hubinger, A.M.; Hughes, J.; Cotmore, S.F.; Harrach, B. Reorganizing the family Parvoviridae: A revised taxonomy independent of the canonical approach based on host association. *Arch. Virol.* 2020, 165, 2133–2146. [CrossRef]

60. Agbandje, M.; McKenna, R.; Rossmann, M.G.; Strassheim, M.L.; Parrish, C.R. Structure Determination of Feline Panleukopenia Virus Empty Capsids. *Proteins* 1993, 16, 155–171. [CrossRef]

61. Agbandje-McKenna, M.; Llamas-Saiz, A.L.; Wang, F.; Tattersall, P.; Rossmann, M.G. Functional implications of the structure of the murine parvovirus, minute virus of mice. *Structure* 1996, 4, 1369–1381. [CrossRef]

62. Simpson, A.A.; Hebert, B.; Sullivan, G.M.; Parrish, C.R.; Zadori, Z.; Tijssen, P.; Rossmann, M.G. The structure of porcine parvovirus: Comparison with related viruses. *J. Mol. Biol.* 2002, 315, 1189–1198. [CrossRef]

63. Simpson, A.A.; Chipman, P.R.; Baker, T.S.; Tijssen, P.; Rossmann, M.G. The structure of an insect parvovirus (*Galleria mellonella* densovirus) at 3.7 Å resolution. *Structure* 1998, 6, 1355–1367. [CrossRef]

64. Chapman, M.S.; Agbandje-McKenna, M. Atomic structure of viral particles. In *Parvoviruses*; Kerr, J.R., Cotmore, S.F., Bloom, M.E., Linden, R.M., Parrish, C.R., Eds.; Hodder Arnold, Ltd.: London, UK, 2006; pp. 107–123.

65. Chapman, M.S.; Rossman, M.G. Structure, sequence, and function correlations among parvoviruses. *Virology* 1993, 194, 491–508. [CrossRef]

66. DeLano, W.L. *The PyMOL Molecular Graphics System*; DeLano Scientific: San Carlos, CA, USA, 2002.

67. Gao, G.; Alvira, M.R.; Somanathan, S.; Lu, Y.; Vandenberghe, L.H.; Rux, J.J.; Calcedo, R.; Sanniguel, J.; Abbas, Z.; Wilson, J.M. Adeno-associated viruses undergo substantial evolution in primates during natural infections. *Proc. Natl. Acad. Sci. USA* 2003, 100, 6081–6086. [CrossRef] [PubMed]

68. Zhu, C.; Wang, C.; Wu, J.; Ye, F.; Lv, R.; Hu, D.; Ai, L.; Yang, L.; Wu, T.; Li, B.; et al. Distribution and genetic diversity of adeno-associated viruses in bats from coastal areas of Southeast China. *Sci. Rep.* 2020, 10, 3725. [CrossRef] [PubMed]

69. Li, Y.; Ge, X.; Hon, C.C.; Zhang, H.; Zhou, P.; Zhang, Y.; Wu, Y.; Wang, L.E.; Shi, Z. Prevalence and genetic diversity of adeno-associated viruses in bats from China. *J. Gen. Virol.* 2010, 91, 2601–2609. [CrossRef] [PubMed]

70. Li, Y.; Li, J.; Liu, Y.; Shi, Z.; Liu, H.; Wei, Y.; Yang, L. Bat adeno-associated viruses as gene therapy vectors with the potential to evade human neutralizing antibodies. *Gene Ther.* 2019, 26, 264–276. [CrossRef]

71. Hoggan, M.D.; Blacklow, N.R.; Rowe, W.P. Studies of small DNA viruses found in various adenovirus preparations: Physical, biological, and immunological characteristics. *Proc. Natl. Acad. Sci. USA* 1966, 55, 1467–1474. [CrossRef] [PubMed]

72. Muramatsu, S.; Mizukami, H.; Young, N.S.; Brown, K.E. Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. *Virology* 1996, 221, 208–217. [CrossRef]

73. Rutledge, E.; Halbert, C.; Russell, D. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. *J. Virol.* 1998, 72, 309–319. [CrossRef] [PubMed]
74. Chen, C.L.; Jensen, R.L.; Schnepp, B.C.; Connell, M.J.; Shell, R.; Siera, T.J.; Bartlett, J.S.; Clark, K.R.; Johnson, P.R. Molecular characterization of adenovirus-associated viruses infecting children. J. Virol. 2005, 79, 14781–14792. [CrossRef]

75. Cabanes-Creus, M.; Hallwirth, C.V.; Weshaus, A.; Ng, B.H.; Liao, S.H.Y.; Zhu, E.; Navarro, R.G.; Baltazar, G.; Drouyer, M.; Scott, S.; et al. Restoring the natural tropism of AAV2 vectors for human liver. Sci. Transl. Med. 2020, 12, eaba3312. [CrossRef]

76. Cabanes-Creus, M.; Westhaus, A.; Navarro, R.G.; Baltazar, G.; Zhu, E.; Amaya, A.K.; Liao, S.H.Y.; Scott, S.; Tallard, E.; Dilworth, K.L.; et al. Attenuation of Heparan Sulfate Proteoglycan Binding Enhances In Vivo Transduction of Human Primary Hepatocytes with AAV2. Mol. Ther. Methods Clin. Dev. 2020, 17, 1139–1154. [CrossRef] [PubMed]

77. Hsu, H.L.; Brown, A.; Loveland, A.B.; Lotun, A.; Xu, M.; Luo, L.; Xu, G.; Li, J.; Ren, L.; Su, Q.; et al. Structural characterization of a novel human adenovirus-associated virus capsid with neurotropic properties. Nat. Commun. 2020, 11, 3279. [CrossRef] [PubMed]

78. Hildebrandt, E.; Penzes, J.J.; Gifford, R.J.; Agbandje-Mckenna, M.; Kotin, R.M. Evolution of dependoparvoviruses across geological timescales-implications for design of AAV-based gene therapy vectors. Virus Evol. 2020, 6, vea043. [CrossRef]

79. Finnigan, G.C.; Hansson-Smith, V.; Stevens, T.H.; Thornton, J.W. Evolution of increased complexity in a molecular machine. Nature 2012, 481, 360–364. [CrossRef]

80. Zinn, E.; Pacouret, S.; Khaychuk, V.; Turunen, H.T.; Carvalho, L.S.; Andres-Mateos, E.; Shah, S.; Shelke, R.; Maurer, A.C.; Plovie, E.; et al. In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector. Cell Rep. 2015, 12, 1056–1068. [CrossRef]

81. Santiago-Ortiz, J.; Ojala, D.S.; Westesson, O.; Weinstein, J.R.; Wong, S.Y.; Steinseapir, A.; Kumar, S.; Holmes, I.; Schaffer, D.V. AAV ancestral reconstruction enables selection of broadly infectious viral variants. Gene Ther. 2015, 22, 934–946. [CrossRef]

82. Landegger, L.D.; Pan, B.; Askew, C.; Wassmer, S.J.; Gluck, S.D.; Galvin, A.; Taylor, R.; Forge, A.; Stankovic, K.M.; Holt, J.R.; et al. A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear. Nat. Biotechnol. 2017, 35, 280–284. [CrossRef]

83. Hu, C.J.; Lu, Y.C.; Tsai, Y.H.; Cheng, H.Y.; Takeda, H.; Huang, C.Y.; Xiao, R.; Hsu, C.J.; Tsai, J.W.; Vandenberge, L.H.; et al. Efficient in Utero Gene Transfer to the Mammalian Inner Ears by the Synthetic Adeno-Associated Viral Vector Anc80L65. Mol. Ther. Methods Clin. Dev. 2020, 2019, 493–500. [CrossRef]

84. Gurdia, B.L.; DiMattia, M.A.; Miller, E.B.; Bennett, A.; McKenna, R.; Weichert, W.S.; Nelson, C.D.; Chen, W.J.; Muzyczka, N.; Olson, N.H.; et al. Capsid antibodies to different adenovirus-associated virus serotypes bind common regions. J. Virol. 2013, 87, 9111–9124. [PubMed]

85. Mingozzi, F.; Maus, M.V.; Rannu, D.; Sabatino, D.E.; Murphy, S.L.; Rasko, J.E.; Manno, C.S.; Sommer, J.; Jiang, H.; et al. CD8(+)-T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 2007, 13, 419–422. [CrossRef]

86. Popa-Wagner, R.; Porwal, M.; Koczot, F.; Fabisch, P.; Rose, J.A. Synthesis of adeno-associated virus structural proteins requires both alternative mRNA splicing and alternative initiations from a single transcript. J. Virol. 2014, 88, 6210–6220. [CrossRef] [PubMed]

87. Johnson, J.S.; Li, C.; DiPrimo, N.; Weinberg, M.S.; McCown, T.J.; Samulski, R.J. Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. J. Virol. 2010, 84, 8888–8909. [CrossRef] [PubMed]

88. Wörner, T.P.; Bennett, A.; Habka, S.; Snijder, J.; Friese, O.; Powers, T.; Agbandje-McKenna, M.; Heck, A.J.R. Adeno-associated virus capsid assembly is divergent and stochastic. Nat. Commun. 2021, 12, 1642. [CrossRef]

89. Becerra, S.P.; Koczen, F.; Fabisch, P.; Rose, J.A. Synthesis of adeno-associated virus structural proteins requires both alternative mRNA splicing and alternative initiations from a single transcript. J. Virol. 1988, 62, 2745–2754. [CrossRef]

90. Excoffon, K.J.; Koerber, J.T.; Dickey, D.D.; Murtha, M.; Keshavjee, S.; Kaspar, B.K.; Zabner, J.; Schaffer, D.V. Directed evolution of adeno-associated virus to an infectious respiratory virus. Proc. Natl. Acad. Sci. USA 2009, 106, 3865–3870. [CrossRef]

91. Wang, Q.; Wu, Z.; Zhang, J.; Firmman, J.; Wei, H.; Zhuang, Z.; Liu, L.; Mia, L.; Hu, Y.; Li, D.; et al. A Robust System for Production of Superabundant VP1 Recombinant AAV Vectors. Mol. Ther. Methods Clin. Dev. 2017, 7, 146–156. [CrossRef]

92. Salgani, M.; Venkatakrishnan, B.; Bennett, A.; Lins, B.; Yarbrough, J.; Muzyczka, N.; Agbandje-McKenna, M.; McKenna, R. Evidence for pH-dependent protease activity in the adeno-associated virus capsid. J. Virol. 2012, 86, 11877–11885. [CrossRef] [PubMed]

93. Mietzsch, M.; Broecker, F.; Reinhardt, A.; Seeberger, P.H.; Heilbronn, R. Differential adeno-associated virus serotype-specific interaction patterns with synthetic heparins and other glycans. J. Virol. 2014, 88, 2991–3003. [CrossRef]

94. Mietzsch, M.; Casteleyn, V.; Weger, S.; Zolotukhin, S.; Heilbronn, R. OneBac 2.0: Sf9 Cell Lines for Production of AAV5 Vectors with Enhanced Infectivity and Minimal Encapsidation of Foreign DNA. Hum. Gene Ther. 2015, 26, 688–697. [CrossRef]

95. Fakhiri, J.; Grimm, D. Best of most possible worlds: Hybrid gene therapy vectors based on parvoviruses and heterologous viruses. Mol. Ther. 2021. [CrossRef] [PubMed]

96. Schmit, P.F.; Pacouret, S.; Zinn, E.; Telford, E.; Nicolaou, F.; Broucque, F.; Andres-Mateos, E.; Xiao, R.; Penaud-Budloo, M.; Bouzelha, M.; et al. Cross-Packaging and Capsid Mosaic Formation in Multiplexed AAV Libraries. Mol. Ther. Methods Clin. Dev. 2020, 17, 107–121. [CrossRef] [PubMed]

97. Rabinowitz, J.E.; Rolling, F.; Li, C.; Conrath, H.; Xiao, W.; Xiao, X.; Samulski, R.J. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 2002, 76, 791–801. [CrossRef] [PubMed]
Viruses 2021, 13, 1336

98. Hauck, B.; Xiao, W. Characterization of tissue tropism determinants of adeno-associated virus type 1. J. Virol. 2003, 77, 2768–2774. [CrossRef]

99. Rabinowitz, J.E.; Bowles, D.E.; Faust, S.M.; Ledford, J.G.; Cunningham, S.E.; Samulski, R.J. Cross-dressing the virion: The transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J. Virol. 2004, 78, 4421–4432. [CrossRef]

100. Chai, Z.; Sun, J.; Riggsbee, K.M.; Wang, M.; Samulski, R.J.; Li, C. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion. J. Control. Release 2017, 262, 348–356. [CrossRef]

101. Chai, Z.; Zhang, X.; Dobbins, A.L.; Frost, E.A.; Samulski, R.J.; Li, C. Chimeric Capsid Proteins Impact Transduction Efficiency of Haploid Adeno-Associated Virus Vectors. Viruses 2019, 11, 1138. [CrossRef]

102. Mills, D.R.; Peterson, R.L.; Spiegelman, S. An extracellular Darwinian experiment with a self-duplicating nucleic acid molecule. Proc. Natl. Acad. Sci. USA 1967, 58, 217–224. [CrossRef]

103. Clackson, T.; Hoogenboom, H.R.; Griffiths, A.D.; Winter, G. Making antibody fragments using phage display libraries. Nature 1991, 352, 624–628. [CrossRef] [PubMed]

104. Smith, G.P. filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science 1985, 228, 1315–1317. [CrossRef]

105. Scott, J.K.; Smith, G.P. Searching for peptide ligands with an epitope library. Science 1990, 249, 386–390. [CrossRef] [PubMed]

106. Chen, K.; Arnold, F.H. Tuning the activity of an enzyme for unusual environments: Sequential random mutagenesis of subtilisin E for catalysis in dimethylformamide. Proc. Natl. Acad. Sci. USA 1993, 90, 5618–5622. [CrossRef] [PubMed]

107. Gibney, E.; Van Noorden, R.; Ledford, H.; Castelvecchi, D.; Warren, M. ‘Test-tube’ evolution wins Chemistry Nobel Prize. Nature 2018, 562, 176. [CrossRef]

108. Stemmer, W.P. DNA shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution. Proc. Natl. Acad. Sci. USA 1994, 91, 10747–10751. [CrossRef] [PubMed]

109. Stemmer, W.P. Rapid evolution of a protein in vitro by DNA shuffling. Nature 1994, 370, 389–391. [CrossRef]

110. Lukashov, V.V.; Goudsmit, J. Evolutionary relationships among paroviruses: Virus-host coevolution among autonomous primate paroviruses and links between adeno-associated and avian paroviruses. J. Virol. 2001, 75, 2729–2740. [CrossRef]

111. Senapathy, P.; Carter, B.J. Molecular cloning of adeno-associated virus variant genomes and generation of infectious virus by recombination in mammalian cells. J. Biol. Chem. 1984, 259, 4661–4666. [CrossRef]

112. Bowles, D.E.; Rabinowitz, J.E.; Samulski, R.J. Marker rescue of adeno-associated virus (AAV) capsid mutants: A novel approach for chimeric AAV production. J. Virol. 2003, 77, 423–432. [CrossRef]

113. Perabo, L.; Endell, J.; King, S.; Lux, K.; Goldnau, D.; Hallek, M.; Buning, H. Combinatorial engineering of a gene therapy vector: Directed evolution of adeno-associated virus. J. Gene Med. 2006, 8, 155–162. [CrossRef] [PubMed]

114. Maheshri, N.; Koerber, J.T.; Kaspar, B.K.; Schaffer, D.V. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 2006, 24, 198–204. [CrossRef] [PubMed]

115. Zhao, H.; Giver, L.; Shao, Z.; Affholter, J.A.; Arnold, F.H. Molecular evolution by staggered extension process (STEP) in vitro recombination. Nat. Biotechnol. 1998, 16, 258–261. [CrossRef] [PubMed]

116. Cabanes-Creus, M.; Ginn, S.L.; Amaya, A.K.; Liao, S.H.Y.; Westhaus, A.; Hallwirth, C.V.; Wilmott, P.; Ward, J.; Dilworth, K.L.; Santilli, G.; et al. Codon-Optimization of Wild-Type Adeno-Associated Virus Capsid Sequences Enhances DNA Family Shuffling while Conserving Functionality. Mol. Ther. Methods Clin. Dev. 2019, 12, 71–84. [CrossRef]

117. Soong, N.W.; Nomura, L.; Pekrun, K.; Reed, M.; Sheppard, L.; Dawes, G.; Stemmer, W.P. Molecular breeding of viruses. Nat. Genet. 2000, 25, 436–439. [CrossRef]

118. Locht, A.M.; Tatsuno, G.P.; Christie, B.; McDonnell, J.W.; Zhou, S.; Surosky, R.; Pierce, G.F.; Colosi, P. Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J. Virol. 2006, 80, 821–834. [CrossRef]

119. Meyer, N.L.; Hu, G.; Davulcu, O.; Xie, Q.; Noble, A.J.; Yoshioka, C.; Gingerich, D.S.; Trzynka, A.; David, L.; Stagg, S.M.; et al. Structure of the gene therapy vector, adeno-associated virus with its cell receptor, AAVR. ELife 2019, 8, e44707. [CrossRef]

120. Zhang, R.; Cao, L.; Cui, M.; Sun, Z.; Hu, M.; Zhang, R.; Stuart, W.; Zhao, X.; Yang, Z.; Li, X.; et al. Adeno-associated virus 2 bound to its cellular receptor AAVR. Nat. Microbiol. 2019, 4, 675–682. [CrossRef]

121. Adachi, K.; Enoki, T.; Kawano, Y.; Veraz, M.; Nakai, H. Drawing a high-resolution functional map of adeno-associated virus capsid by massively parallel sequencing. Nat. Commun. 2014, 5, 3075. [CrossRef]

122. Levy, S.F.; Blundell, J.R.; Venkataram, S.; Petrov, D.A.; Fisher, D.S.; Sherlock, G. Quantitative evolutionary dynamics using high-resolution lineage tracking. Nature 2015, 519, 181–186. [CrossRef]

123. Pekrun, K.; De Alencastro, G.; Luo, Q.J.; Liu, J.; Kim, Y.; Nyagaard, S.; Galivo, F.; Zhang, F.; Song, R.; Tiffany, M.R.; et al. Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors. JCI Insight 2019, 4. [CrossRef]

124. de Alencastro, G.; Pekrun, K.; Valdmansis, P.; Tiffany, M.; Xu, J.; Kay, M.A. Tracking Adeno-Associated Virus Capsid Evolution by High-Throughput Sequencing. Hum. Gene Ther. 2020, 31, 553–564. [CrossRef]

125. Mischak, D.; Mendez-Gomez, H.R.; Zolotukhin, S. High-accuracy biodistribution analysis of adeno-associated virus variants by double barcode sequencing. Mol. Ther. Methods Clin. Dev. 2015, 2, 15041. [CrossRef]

126. Herrmann, A.K.; Bender, C.; Kienle, E.; Grosse, S.; El Andari, J.; Botta, J.; Schurmann, N.; Wiedtke, E.; Niopke, D.; Grimm, D. A Robust and All-Inclusive Pipeline for Shuffling of Adeno-Associated Viruses. ACS Synth. Biol. 2019, 8, 194–206. [CrossRef]
127. Davidsson, M.; Diaz-Fernandez, P.; Schwich, O.D.; Torroba, M.; Wang, G.; Bjorklund, T. A novel process of viral barcoding and library preparation enables high-diversity library generation and recombination-free paired-end sequencing. Sci. Rep. 2016, 6, 37563. [CrossRef] [PubMed]

128. Bryant, D.H.; Bashir, A.; Sinai, S.; Jain, N.K.; Ogden, P.J.; Riley, P.F.; Church, G.M.; Colwell, L.J.; Kelsic, E.D. Deep diversification of an AAV capsid by protein engineering. Nat. Biotechnol. 2021, 39, 691–696. [CrossRef]

129. Spector, L.P.; Tiffany, M.; Ferraro, N.M.; Abell, N.S.; Montgomery, S.B.; Kay, M.A. Evaluating the Genome Parameters Governing rAAV-Mediated Homologous Recombination. Mol. Ther. 2021, 29, 1028–1046. [CrossRef] [PubMed]

130. Yang, L.; Jiang, J.; Drouin, L.M.; Agbandje-McKenna, M.; Chen, C.; Qiao, C.; Pu, D.; Hu, X.; Wang, D.Z.; Li, J.; et al. A myocardial tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc. Natl. Acad. Sci. USA 2009, 106, 3946–3951. [CrossRef] [PubMed]

131. Li, W.; Asokan, A.; Wu, Z.; Van Dyke, T.; DiPrimio, N.; Johnson, J.S.; Govindaswamy, L.; Agbandje-McKenna, M.; Leichtle, S.; Redmond, D.E., Jr.; et al. Engineering and selection of shuffled AAV genomes: A new strategy for producing targeted biological nanoparticles. Mol. Ther. 2008, 16, 1252–1260. [CrossRef]

132. Koerber, J.T.; Jang, J.H.; Schaffer, D.V. DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol. Ther. 2008, 16, 1703–1709. [CrossRef]

133. O’Donnell, J.; Taylor, K.A.; Chapman, M.S. Adeno-associated virus-2 and its primary cellular receptor–Cryo-EM structure of a heparin complex. Virolology 2009, 385, 434–443. [CrossRef]

134. Wobus, C.E.; Hugle-Dorr, B.; Girod, A.; Petersen, G.; Hallek, M.; Kleinschmidt, J.A. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: Epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 2000, 74, 9281–9293. [CrossRef]

135. McCraw, D.M.; O’Donnell, J.K.; Taylor, K.A.; Stagg, S.M.; Chapman, M.S. Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20. Virology 2012, 431, 40–49. [CrossRef]

136. Foust, K.D.; Nurre, E.; Montgomery, C.L.; Hernandez, A.; Chan, C.M.; Kaspar, B.K. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 2009, 27, 59–65. [CrossRef]

137. Duque, S.; Joussemet, B.; Riviere, C.; Marais, T.; Dubreil, L.; Douar, A.M.; Fyfe, J.; Moullier, P.; Collé, M.A.; Barkats, M. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Ther. 2009, 17, 1187–1196. [CrossRef] [PubMed]

138. Bevan, A.K.; Duque, S.; Foustd, K.D.; Morales, P.R.; Braun, L.; Schmelzer, L.; Chan, C.M.; McCrate, M.; Chicoine, L.G.; Coley, B.D.; et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol. Ther. 2011, 19, 1971–1980. [CrossRef] [PubMed]

139. Deverman, B.E.; Pravdo, P.L.; Simpson, B.P.; Kumar, S.R.; Chan, K.Y.; Banerjee, A.; Wu, W.L.; Yang, B.; Huber, N.; Pasca, S.P.; et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 2016, 34, 204–209. [CrossRef] [PubMed]

140. Hordeaux, J.; Wang, Q.; Katz, N.; Buza, E.L.; Bell, P.; Wilson, J.M. The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. Mol. Ther. 2018, 26, 664–668. [CrossRef] [PubMed]

141. Hordeaux, J.; Yuan, Y.; Clark, P.M.; Wang, Q.; Martino, R.A.; Sins, J.J.; Bell, P.; Raymond, A.; Stanford, W.L.; Wilson, J.M. The GPI-Linked Protein LY6A Drives AAV-PHP.B Transport across the Blood-Brain Barrier. Mol. Ther. 2019, 27, 912–921. [CrossRef]

142. Nonnenmacher, M.; Weber, T. Adeno-associated virus 2 infection requires endocytosis through the CLIC/GEEC pathway. Cell Host Microbe 2011, 10, 563–576. [CrossRef] [PubMed]

143. Di Pasquale, G.; Chiorni, J.A. AAV transcytosis through barrier epithelia and endothelium. Mol. Ther. 2006, 13, 506–516. [CrossRef] [PubMed]

144. Hanlon, K.S.; Meltzer, J.C.; Buzhdagian, T.; Cheng, M.J.; Sena-Esteves, M.; Bennett, R.E.; Sullivan, T.P.; Razmpour, R.; Gong, Y.; Ng, C.; et al. Selection of an Efficient AAV Vector for Robust CNS Transgene Expression. Mol. Ther. Methods Clin. Dev. 2019, 15, 320–332. [CrossRef]

145. Perabo, L.; Goldnau, D.; White, K.; Endell, J.; Boucas, J.; Humme, S.; Work, L.M.; Janicki, H.; Hallek, M.; Baker, A.H.; et al. Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. J. Virol. 2006, 80, 7265–7269. [CrossRef]

146. Girod, A.; Ried, M.; Wobus, C.; Lahm, H.; Leike, K.; Kleinschmidt, J.; Deleage, G.; Hallek, M. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat. Med. 1999, 5, 1052–1056. [CrossRef]

147. Moskalenko, M.; Chen, L.; van Roey, M.; Donahue, B.A.; Snyder, R.O.; McArthur, J.G.; Patel, S.D. Epitope mapping of human anti-adenovirus-associated virus type 2 neutralizing antibodies: Implications for gene therapy and virus structure. J. Virol. 2000, 74, 1761–1766. [CrossRef]

148. Wu, P.; Xiao, W.; Conlon, T.; Hughes, J.; Agbandje-McKenna, M.; Ferkol, T.; Flotte, T.; Muzyczka, N. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 2000, 74, 8635–8647. [CrossRef] [PubMed]

149. Gao, W.; Mahajan, S.P.; Sulam, J.; Gray, J.J. Deep Learning in Protein Structural Modeling and Design. Patterns 2020, 1, 100142. [CrossRef] [PubMed]

150. Marques, A.D.; Kummer, M.; Kondratov, O.; Banerjee, A.; Moskalenko, O.; Zolotukhin, S. Applying machine learning to predict viral assembly for adeno-associated virus capsid libraries. Mol. Ther. Methods Clin. Dev. 2021, 20, 276–286. [CrossRef]
151. Havlik, L.P.; Simon, K.E.; Smith, J.K.; Kline, K.A.; Tse, L.V.; Oh, D.K.; Fanous, M.M.; Meganck, R.M.; Mietzsch, M.; Kleinschmidt, J.; et al. Coevolution of Adeno-associated Virus Capsid Antigenicity and Tropism through a Structure-Guided Approach. J. Virol. 2020, 94. [CrossRef]

152. Fromm, J.R.; Hileman, R.E.; Caldwell, E.E.; Weiler, J.M.; Linhardt, R.J. Differences in the interaction of heparin with arginine and lysine and the importance of these basic amino acids in the binding of heparin to acidic fibroblast growth factor. Arch. Biochem. Biophys. 1995, 323, 279–287. [CrossRef]

153. Conrad, H.E. Heparin-Binding Proteins, 1st ed.; Academic Press: San Diego, CA, USA, 1998; p. 527.

154. Capila, I.; Linhardt, R.J. Heparin-protein interactions. Angew. Chem. Int. Ed. Engl. 2002, 41, 391–412. [CrossRef]

155. Kern, A.; Schmidt, K.; Leder, C.; Muller, O.J.; Wobus, C.E.; Bettinger, K.; Von der Lieth, C.W.; King, J.A.; Kleinschmidt, J.A. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J. Virol. 2003, 77, 11072–11081. [CrossRef]

156. Opie, S.R.; Warrington, K.H., Jr.; Agbandje-McKenna, M.; Zolotukhin, S.; Muzyczka, N. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 2003, 77, 6995–7006. [CrossRef]

157. Lerch, T.F.; Chapman, M.S. Identification of the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology 2012, 423, 6–13. [CrossRef]

158. Afione, S.; DiMattia, M.A.; Halder, S.; Di Pasquale, G.; Agbandje-McKenna, M.; Chiorini, J.A. Identification and mutagenesis of the adeno-associated virus 5 sialic acid binding region. J. Virol. 2015, 89, 1660–1672. [CrossRef] [PubMed]

159. Huang, L.Y.; Patel, A.; Ng, R.; Miller, E.B.; Halder, S.; McKenna, R.; Asokan, A.; Agbandje-McKenna, M. Characterization of the Adeno-associated virus 1 and 6 sialic acid binding site. J. Virol. 2016. [CrossRef] [PubMed]

160. Xie, Q.; Spear, J.M.; Noble, A.J.; Sousa, D.R.; Meyer, N.L.; Davulcu, O.; Zhang, F.; Linhardt, R.J.; Stagg, S.M.; Chapman, M.S. The 2.8 A Electron Microscopy Structure of Adeno-Associated Virus-DJ Bound by a Heparinoid Pentasaccharide. Mol. Ther. Methods Clin. Dev. 2017, 5, 1–12. [CrossRef]

161. Handa, A.; Muramatsu, S.; Qiu, J.; Mizukami, H.; Brown, K.E. Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors. J. Gen. Virol. 2000, 81, 2077–2084. [CrossRef] [PubMed]

162. Levy, H.C.; Bowman, V.D.; Govindasamy, L.; McKenna, R.; Nash, K.; Warrington, K.; Chen, W.; Muzyczka, N.; Yan, X.; Baker, T.S.; et al. Heparin binding induces conformational changes in Adeno-associated virus serotype 2. J. Struct. Biol. 2009, 165, 146–156. [CrossRef]

163. Connell, B.J.; Lortat-Jacob, H. Human Immunodeficiency Virus and Heparan Sulfate: From Attachment to Entry Inhibition. Front. Immunol. 2013, 4, 385. [CrossRef] [PubMed]

164. Xie, Q.; Spilman, M.; Meyer, N.L.; Lerch, T.F.; Stagg, S.M.; Chapman, M.S. Electron microscopy analysis of a disaccharide analog complex reveals receptor interactions of adeno-associated virus. J. Struct. Biol. 2013, 184, 129–135. [CrossRef]

165. Zhang, F.; Aguiler, J.; Beaudet, J.M.; Xie, Q.; Lerch, T.F.; Davulcu, O.; Colon, W.; Chapman, M.S.; Linhardt, R.J. Characterization of interactions between heparin/glycosaminoglycan and adeno-associated virus. Biochemistry 2013, 52, 6275–6285. [CrossRef] [PubMed]

166. Levy, H.C.; Bowman, V.D.; Govindasamy, L.; McKenna, R.; Nash, K.; Warrington, K.; Chen, W.; Muzyczka, N.; Yan, X.; Baker, T.S.; et al. Heparin binding induces conformational changes in Adeno-associated virus serotype 2. J. Struct. Biol. 2009, 165, 146–156. [CrossRef]

167. Handa, A.; Muramatsu, S.; Qiu, J.; Mizukami, H.; Brown, K.E. Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors. J. Gen. Virol. 2000, 81, 2077–2084. [CrossRef] [PubMed]

168. Levy, H.C.; Bowman, V.D.; Govindasamy, L.; McKenna, R.; Nash, K.; Warrington, K.; Chen, W.; Muzyczka, N.; Yan, X.; Baker, T.S.; et al. Heparin binding induces conformational changes in Adeno-associated virus serotype 2. J. Struct. Biol. 2009, 165, 146–156. [CrossRef]

169. Lopez-Bueno, A.; Rubio, M.P.; Bryant, N.; McKenna, R.; Agbandje-McKenna, M.; Almendral, J.M. Host-selected amino acid changes at the sialic acid binding pocket of the parvovirus capsid modulate cell binding affinity and determine virulence. J. Virol. 2006, 80, 1563–1573. [CrossRef] [PubMed]

170. Hirst, G.K. The Agglutination of Red Cells by Allantoic Fluid of Chick Embryos Infected with Influenza Virus. Science 1941, 94, 22–23. [CrossRef] [PubMed]

171. McClelland, L.; Hare, R. The adsorption of influenza virus by red cells and a new in vitro method of measuring antibodies for influenza virus. Can. Public Health J. 1941, 32, 530–538.

172. Kuchipudi, S.V.; Nelli, R.K.; Gontu, A.; Satyakumar, R.; Surendran Nair, M.; Subbiah, M. Sialic Acid Receptors: The Key to Solving the Enigma of Zoonotic Virus Spillover. Viruses 2021, 13, 262. [CrossRef] [PubMed]

173. Lopez-Bueno, A.; Rubio, M.P.; Bryant, N.; McKenna, R.; Agbandje-McKenna, M.; Almendral, J.M. Host-selected amino acid changes at the sialic acid binding pocket of the parvovirus capsid modulate cell binding affinity and determine virulence. J. Virol. 2006, 80, 1563–1573. [CrossRef] [PubMed]

174. Palermo, L.M.; Hafenstein, S.L.; Parrish, C.R. Purified feline and canine transferrin receptors reveal complex interactions with the capsids of canine and feline parvoviruses that correspond to their host ranges. J. Virol. 2006, 80, 8482–8492. [CrossRef] [PubMed]

175. Kaludov, N.; Brown, K.E.; Walters, R.W.; Zabner, J.; Chiorini, J.A. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J. Virol. 2001, 75, 6884–6893. [CrossRef]

176. Wu, Z.; Miller, E.; Agbandje-McKenna, M.; Samulski, R.J. Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J. Virol. 2006, 80, 9093–9103. [CrossRef]

177. Shen, S.; Bryant, K.D.; Brown, S.M.; Randell, S.H.; Asokan, A. Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J. Biol. Chem. 2011, 286, 13532–13540. [CrossRef]

178. Bell, C.L.; Gurd, B.L.; Van Vliet, K.; Agbandje-McKenna, M.; Wilson, J.M. Identification of the galactose binding domain of the AAV9 capsid. J. Virol. 2012, 86, 7326–7333. [CrossRef]

179. Qing, K.; Mah, C.; Hansen, J.; Zhou, S.; Dwarki, V.; Srivastava, A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. 1999, 5, 71–77. [CrossRef]
176. Kashiwakura, Y.; Tamayose, K.; Iwabuchi, K.; Hirai, Y.; Shimada, T.; Matsumoto, K.; Nakamura, T.; Watanabe, M.; Oshimi, K.; Daida, H. Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. *J. Virol.* 2005, 79, 609–614. [CrossRef]

177. Di Pasquale, G.; Davidson, B.L.; Stein, C.S.; Martins, I.; Scudiero, D.; Monks, A.; Chiorini, J.A. Identification of PDGFR as a receptor for AAV-5 transduction. *Nat. Med.* 2003, 9, 1306–1312. [CrossRef]

178. Weller, M.L.; Amornphimoltham, P.; Schmidt, M.; Wilson, P.A.; Gutkind, J.S.; Chiorini, J.A. Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. *Nat. Med.* 2010, 16, 662–664. [CrossRef] [PubMed]

179. Summerford, C.; Bartlett, J.S.; Samulski, R.J. AlphaVbeta5 integrin: A co-receptor for adeno-associated virus type 2 infection. *Nat. Med.* 1999, 5, 78–82. [CrossRef]

180. Qiu, J.; Brown, K.E. Integrin alphaVbeta5 is not involved in adeno-associated virus type 2 (AAV2) infection. *Virology* 1999, 264, 436–440. [CrossRef] [PubMed]

181. Asokan, A.; Hamra, J.B.; Govindasamy, L.; Agbandje-McKenna, M.; Samulski, R.J. Adeno-associated virus type 2 contains an integrin alphaVbeta1 binding domain essential for viral cell entry. *J. Virol.* 2006, 80, 8961–8969. [CrossRef] [PubMed]

182. Akache, B.; Grimm, D.; Pandey, K.; Yant, S.R.; Xu, H.; Kay, M.A. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. *J. Virol.* 2006, 80, 9831–9836. [CrossRef]

183. Mizukami, H.; Young, N.; Brown, K. Adeno-associated virus type 2 binds to a 150-kilodalton cell membrane glyco protein. *Virology* 1996, 217, 124–130. [CrossRef] [PubMed]

184. Carette, J.E.; Guimaraes, C.P.; Wueptrich, I.; Blomen, V.A.; Varadarajan, M.; Samulski, R.J. Heparan Sulfate Binding Promotes Accumulation of Intravitreally Associated Virus VP1u Exhibits Protease Activity. *J. Virol.* 2002, 76, 2014–2018. [CrossRef] [PubMed]

185. Hamilton, B.A.; Li, X.; Pezzulo, A.A.; Abou Alaiwa, M.H.; Zabner, J. Polarized AAVR expression determines infectivity by AAV virus type 2 capsid leads to the exposure of hidden VP1 N termini. *J. Virol.* 2005, 79, 5296–5303. [CrossRef]

186. Pillay, S.; Zou, W.; Cheng, F.; Puschnik, A.S.; Meyer, N.L.; Ganaie, S.S.; Deng, X.; Wosen, J.E.; Davulcu, O.; Yan, Z.; et al. AAV serotype have distinctive interactions with domains of the cellular receptor AAVR. *J. Virol.* 2017, 91, e0391-17. [CrossRef]

187. Bhella, D. The role of cellular adhesion molecules in virus attachment and entry. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 2015, 370, 20140035. [CrossRef]

188. Silveria, M.A.; Large, E.E.; Zane, G.M.; White, T.A.; Chapman, M.S. The Structure of an AAV5-AAV Complex at 2.5 Å Resolution: Implications for Cellular Entry and Immune Neutralization of AAV Gene Therapy Vectors. *Viruses* 2020, 12, 1326. [CrossRef] [PubMed]

189. Zhang, R.; Xu, G.; Cao, L.; Sun, Z.; He, Y.; Cui, M.; Sun, Y.; Li, S.; Li, H.; Qin, L.; et al. Divergent engagements between adeno-associated viruses with their cellular receptor AAVR. *Nat. Commun.* 2019, 10, 3760. [CrossRef] [PubMed]

190. Dudek, A.M.; Zabaleta, N.; Zinn, E.; Pillay, S.; Cheng, F.; Qi, J.; Carette, J.E.; Wosen, J.E.; Vandenberghe, L.H. An Alternate Route for Adeno-Associated Virus (AAV) Entry Independent of AAV Receptor. *J. Virol.* 2018, 92. [CrossRef]

191. Meisen, W.H.; Nejad, Z.B.; Hardy, M.; Zhao, H.; Oliverio, O.; Wang, S.; Hale, C.; Ollmann, M.M.; Collins, P.J. Pooled Screens Identify GPR108 and TM9SF2 as Host Cell Factors Critical for AAV Transduction. *Mol. Ther. Methods Clin. Dev.* 2020, 80, 286–381. [CrossRef]

192. Madigan, V.J.; Tyson, T.O.; Yuziuk, J.A.; Pillai, M.; Moller-Tank, S.; Asokan, A. A CRISPR screen identifies the cell polarity determinant Crumbs 3 as an AAV restriction factor in hepatocytes. *J. Virol.* 2019. [CrossRef]

193. Micaroni, M.; Perinetti, G.; Berrie, C.P.; Mironov, A.A. The SPCA1 Ca^{2+} pump and intracellular membrane trafficking. *Traffic* 2010, 11, 1315–1333. [CrossRef]

194. Dorsch, S.; Liebisch, G.; Kaufmann, B.; von Landenberg, P.; Hoffmann, J.H.; Drobnik, W.; Modrow, S. The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. *J. Virol.* 2002, 76, 2014–2018. [CrossRef] [PubMed]

195. Kurian, J.J.; Lakshmanan, R.; Chmely, W.M.; Hull, J.A.; Yu, J.C.; Bennett, A.; McKenna, R.; Agbandje-McKenna, M. Adeno-Associated Virus VP1u Exhibits Protease Activity. *Viruses* 2019, 11, 399. [CrossRef] [PubMed]

196. Erli, H.C.J. T Cell-Mediated Immune Responses to AAV and AAV Vectors. *Front. Immunol.* 2021, 12. [CrossRef] [PubMed]

197. Woodard, K.T.; Liang, K.J.; Bennett, W.C.; Samulski, R.J. Heparan Sulfate Binding Promotes Accumulation of Intravitreally Delivered Adeno-associated Viral Vectors at the Retina for Enhanced Transduction but Weakly Influences Tropism. *J. Virol.* 2016, 90, 9878–9888. [CrossRef] [PubMed]

198. Stroh, L.J.; Stehle, T. Glycan Engagement by Viruses: Receptor Switches and Specificity. *Annu. Rev. Virol.* 2014, 1, 285–306. [CrossRef] [PubMed]

199. Thompson, A.J.; de Vries, R.P.; Paulson, J.C. Virus recognition of glycan receptors. *Curr. Opin. Virol.* 2019, 34, 117–129. [CrossRef] [PubMed]